

## CURRICULUM VITAE

### I. PERSONAL DATA

- A. **Name:** James R. Anderson, Ph.D.
- B. **Work Address:** Retired
- C. **Home address and Telephone:** 308 South Main Street, North Wales, PA 1945  
402-981-0217

### II. EDUCATION

<u>School</u>	<u>Date</u>	<u>Major/Minor Courses</u>	<u>Degree</u>
University of Washington	1973-1979	Biostatistics	PhD
State University of New York at Buffalo	1969-1973	Mathematics	BA

### III. MERCK/MRL EMPLOYMENT HISTORY

<u>Title</u>	<u>From - To</u>
Distinguished Scientist	2015 - 2023

### IV. NON-MERCK EMPLOYMENT HISTORY

<u>Title</u>	<u>From - To</u>
Director, Frontier Science-Madison office	2014-2015
Visiting Professor (CHS track), Dept. of Biostatistics & Medical Informatics, UW-Madison	2014-2015
Adjunct Professor of Biostatistics, Institute for Health and Society (secondary appointment, Department of Medicine), Medical College of Wisconsin	2014-2015
Associate Dean for Research, College of Public Health, University of Nebraska Medical Center, Omaha, NE	2009-2013
Professor, Department of Biostatistics, College of Public Health, University of Nebraska Medical Center, Omaha, NE	2007-2014
Interim Chairman, Department of Epidemiology, College of Public Health, University of Nebraska Medical Center, Omaha, NE	2007-2009
Professor and Chairman, Department of Preventative and Societal Medicine, College of Medicine, University of	1989-2007

Nebraska Medical Center, Omaha, NE	
Associate Professor, Dana-Farber Cancer Institute, Boston, MA	1986-1989
Associate Professor, Dept. of Biostatistics, Harvard School of Public Health, Boston, MA	1986-1989
Assistant Professor, Department of Biostatistics, Harvard School of Public Health, Boston, MA	1981-1986
Assistant Professor, Dana-Farber Cancer Institute, Boston, MA	1981-1986
Lecturer, Department of Biostatistics, Harvard School of Public Health, Boston, MA	1980-1981
Visiting Assistant Scientist, Sidney Farber Cancer Institute, Boston, MA	1981-1981
Assistant Professor, Dept. of Community & Family Medicine, Univ. of Southern California, Los Angeles, CA	1979-1980
Instructor, Dept. of Community & Family Medicine, Univ. of Southern California, Los Angeles, CA	1977-1979

**V. ACADEMIC EXPERIENCE**

**VI. TRAINING** (Beyond formal education: e.g., courses, ACS short courses etc., which help in advancement in one's professional career.)

<u>Source</u>	<u>Date</u>	<u>Type</u>	<u>Certification</u>
---------------	-------------	-------------	----------------------

**VII. SOCIETY MEMBERSHIPS** (offices held and when)

1980-present	Member, American Society of Clinical Oncology
2013-present	Honorary Member, Gamma Omicron Chapter of Delta Omega
2013-2014	Member, American Statistical Association
2010-2015	Member, Society of Clinical Trials
2008-2014	Member, Public Health Association of Nebraska

**VIII. ACADEMIC AND PROFESSIONAL HONORS**

2011	Spirit of Service Award, University of Nebraska Medical Center Alumni Association, Omaha, NE
2007	Distinguished Scientist Award, University of Nebraska Medical Center, Omaha, NE

**IX. PUBLICATIONS AND PATENTS** (Chronological listing -- oldest first. Add most recent to list. List Publications, Patents, Abstracts and Presentations separately.)

Refereed Articles

1. Krivit W, Chilcote R, Pyesmany A, **Anderson J**, Hammond D. An initial report of a phase-III trial comparing vindesine and vincristine for acute lymphocytic leukemia of childhood. *Cancer Chemotherapy and Pharmacology*. 2(4): 267-70. 1979.
2. Pike MC, **Anderson J**, Day N. Some insights into Miettinen's multivariate confounder score approach to case-control study analysis. *Epidemiology and Community Health*. 33(1): 1046. 1979.
3. Krivit W, **Anderson J**, Chilcote R, Pyesmany A, Chard R, Hammond D. A study of the cross resistance of Vincristine and Vindesine in reinduction therapy for acute lymphocytic leukemia in relapse: A report for Children's Cancer Study Group. *American Journal of Pediatric Hematology/Oncology*. 2: 217-221. 1980.
4. Krivit W, **Anderson J**, Chilcote R, Pyesmany A, Chard R, Hammond D. Comparison of vincristine utilized simultaneously or 24 hours before cyclophosphamide in maintenance regimen of acute lymphoblas. *The American Journal of Pediatric Hematology/Oncology*. 3(3): 227-31. 1981.
5. Jenkin R, **Anderson J**, Jereb B, Thompson J, Pyesmany A, Wara W, Hammond D. Nasopharyngeal carcinoma in the young: A review of Children's Cancer Study Group experience 1960-1977. *Cancer*. 47: 360-366. 1981.
6. Bernstein L, **Anderson J**, Pike MC. Estimating the proportional hazard in two treatment group clinical trials. *Biometrics*. 37:513-520. 1981.
7. **Anderson J**, Krivit W, Chilcote R, Pyesmany A, Chard R, Hammond D. A comparison of the therapeutic response to Vindesine vs. Vincristine of patients with acute lymphoblastic leukemia of childhood in relapse (a phase III trial): A report from Children's Cancer Study Group. *Cancer Treatment Reports*. 65: 1015-1019. 1981.
8. O'Connell MJ, **Anderson J**, Merrill JM, Bennett JM, Glick JH, Berard CW, Neiman RS, Brodovsky HS. Comparative trial of two teniposide-based combination chemotherapy regimens for the treatment of advanced malignant lymphomas. *Cancer Treatment Reports*. 66(12): 2021-5. 1982.
9. **Anderson JR**, Bernstein L, Pike MC. Approximate confidence intervals for probabilities of survival and quantiles in life-table analysis. *Biometrics*. 38(2): 407-16. 1982.
10. **Anderson JR**, Wilson JF, Jenkin DT, Meadows AT, Kersey J, Chilcote RR, Coccia P, Exelby P, Kushner J, Siegel S, Hammond D. Childhood non-Hodgkin's lymphoma. The results of a randomized therapeutic trial comparing a 4-drug regimen (COMP) with a 10-drug regimen (LSA2-L2). *The New England Journal of Medicine*. 308(10): 559-65. 1983.
11. **Anderson JR**, Cain KC, Gelber RD. Analysis of survival by tumor response. *Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology*. 1(11): 710-9. 1983.
12. **Anderson J**, Jenkin RDT. Treatment of Childhood Non-Hodgkin's Lymphoma (letter). *New England Journal of Medicine*. 309:311. 1983.
13. Bakemeier RF, **Anderson JR**, Costello W, Rosner G, Horton J, Glick JH, Hines JD, Berard CW, DeVita VT. BCVPP chemotherapy for advanced Hodgkin's disease: evidence for greater duration of complete remission, greater survival, and le. *Annals of Internal Medicine*. 101(4): 447-56. 1984.
14. Jenkin RD, **Anderson JR**, Chilcote RR, Coccia PF, Exelby PR, Kersey JH, Kushner JH, Meadows AT, Siegel SE, Sposto R. The treatment of localized non-Hodgkin's lymphoma in children: a report from the Children's Cancer Study Group. *Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology*. 2(2): 88-97. 1984.

15. Wilson JF, Jenkin RD, **Anderson JR**, Chilcote RR, Coccia P, Exelby PR, Kersey J, Kjeldsberg CR, Kushner J, Meadows A. Studies on the pathology of non-Hodgkin's lymphoma of childhood. I. The role of routine histopathology as a prognostic factor. A report from the Children's Cancer Study Group. *Cancer*. 53(8): 1695-704. 1984.
16. Gottlieb AJ, Weinberg V, Ellison RR, Henderson ES, Terebelo H, Rafla S, Cuttner J, Silver RT, Cary RW, Levy RN, Hutchinson JL, Raich P, Cooper MR, Wiernik P, **Anderson JR**, Holland JF. Efficacy of Daunorubicin in the therapy of adult acute lymphocytic leukemia: A prospective randomized trial by Cancer and Leukemia, Group B. *Blood*. 67: 267-274. 1984.
17. Jenkin R, **Anderson J**, Chilcote R, Coccia P, Exelby P, Kersey J, Kushner J, Meadows A, Siegel S, Sposto R, Wilson J, Hammond G. The treatment of localized non-Hodgkin's lymphoma in children: A report from the Children's Cancer Study Group. *Journal of Clinical Oncology*. 2: 88-97. 1984.
18. Johnson GJ, Oken MM, **Anderson JR**, O'Connell MJ, Glick JH. Central nervous system relapse in unfavorable histology non-Hodgkin's lymphoma: Is prophylaxis indicated? *Lancet*. 2: 685-687. 1984.
19. Ezdinli EZ, **Anderson JR**, Melvin F, Glick JH, Davis TE, O'Connell MJ. Moderate versus aggressive chemotherapy of nodular lymphocytic poorly differentiated lymphoma. *Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology*. 3(6): 769-75. 1985.
20. **Anderson JR**, Cain KC, Gelber RD, Gelman RS. Analysis and interpretation of the comparison of survival by treatment outcome variables in cancer clinical trials. *Cancer Treatment Reports*. 69(10): 1139-46. 1985.
21. Budman DR, **Anderson J**, Obrecht JP, Canellos GP, Creaven P, Norton L, Gottlieb A. Treatment of refractory Hodgkin's disease with teniposide, cisplatin, hexamethylmelamine, and prednisolone: cancer and leukemia group B trial 8171. *Cancer Treatment Reports*.. 69(6): 719-20. 1985.
22. Schilsky RL, Green MR, **Anderson J**. Cytarabine-cis-platin interactions in patients with advanced cancer. *Seminars in oncology*. 12(2 Suppl 3): 171-6. 1985.
23. **Anderson JR**, Bernstein L. Asymptotically efficient two-step estimators of the hazards ratio for follow-up studies and survival data. *Biometrics*. 41(3): 733-9. 1985.
24. **Anderson JR**, Anderson KM. Further Comparison of Two Methods for Calculating Expected Mortality (letter). *Statistics in Medicine*. 4: 107-108. 1985.
25. **Anderson JR**. Letter to the Editor, comments on Lilienfeld and Pyne (*Statistics in Medicine*, 3:15 26). *Statistics in Medicine*. 4: 237-238. 1985.
26. Carey RW, **Anderson JR**, Green M, Ellison RR, Nathanson L, Kennedy BJ. Treatment of metastatic malignant melanoma with vinblastine, dacarbazine, and cisplatin: a report from the Cancer and Leukemia G. *Cancer Treatment Reports*. 70(3): 329-31. 1986.
27. Vinciguerra V, Probert KJ, Coleman M, **Anderson JR**, Stutzman L, Pajak TF, Nissen NI, Frizzera G, Gottlieb A, Holland JF. Alternating cycles of combination chemotherapy for patients with recurrent Hodgkin's disease following radiotherapy. A prospecti. *Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology*. 4(6): 838-46. 1986.
28. **Anderson JR**, Davis RB. Analysis of survival by tumor response. *Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology*. 4(1): 115-7. 1986.
29. Probert KJ, **Anderson JR**, Barcos M, Gottlieb AJ. The pathologic and clinical heterogeneity of lymphocyte-depleted Hodgkin's disease. *Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology*. 4(9): 1419-20. 1986.
30. **Anderson JR**, Ginsberg S, Gottlieb AJ. Chemotherapy of diffuse large-cell lymphoma--rapidly responding patients have more durable remissions. *Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology*. 4(9): 1420-1. 1986.

31. **Anderson JR**, Davis RJ. Response to letter to the editor. *Journal of Clinical Oncology*. 4:1013. 1986.
32. **Anderson JR**, Davis RD. Response to letter to the editor. *Journal of Clinical Oncology*. 4:1422. 1986.
33. **Anderson JR**, Korzun AH. Response to letter to the editor. *New England Journal of Medicine*. 315(17): 1092. 1986.
34. Rybak ME, **Anderson JR**, Poulin PF, Amrein P, Canellos GP, Gottlieb AJ. A Phase II trial of methanesulfonamide 4' (9 aridinyl amino) (m AMSA) therapy in refractory Hodgkin's disease and non-Hodgkin's lymphoma: Cancer and Leukemia Group B study. *Cancer Treatment Reports*. 70: 1233-1234. 1986.
35. Ezdinli EZ, Harrington DP, Kucuk O, Silverstein MW, **Anderson J**, O'Connell MJ. The effect of intensive intermittent maintenance therapy in advanced low-grade non-Hodgkin's lymphoma. *Cancer*. 60(2): 156-60. 1987.
36. Evans AE, D'Angio GJ, Probert K, **Anderson J**, Hann HW. Prognostic factor in neuroblastoma. *Cancer*. 59(11): 1853-9. 1987.
37. Jenkin RD, Boesel C, Ertel I, Evans A, Hittle R, Ortega J, Sposto R, Wara W, Wilson C, **Anderson J**. Brain-stem tumors in childhood: a prospective randomized trial of irradiation with and without adjuvant CCNU, VCR, and prednisone. *Journal of Neurosurgery*. 66(2): 227-33. 1987.
38. Ozer H, **Anderson JR**, Budman D, Henderson E, Bloomfield CD, Gottlieb A. Combination trial of subcutaneous alpha-2 interferon and oral cyclophosphamide in favorable histology non-Hodgkin's lymphoma. *Investigational New Drugs*. 5: 27-33. 1987.
39. Case DC, **Anderson J**, Ervin TJ, Gottlieb A. Phase II trial of ifosfamide and mesna in previously treated patients with non-Hodgkin's lymphoma: Cancer and Leukemia Group B Study 8552. *Medical and Pediatric Oncology*. 16(3): 182-6. 1988.
40. Lachant NA, **Anderson J**, Ginsberg SJ, Cooper MR, Hurd DD, Bloomfield CD, Gottlieb AJ. Treatment of refractory lymphoma with methotrexate, VM-26 (teniposide), procarbazine, and dexamethasone: Cancer and Leukemia Group B study 7902. *Medical and Pediatric Oncology*. 16(6): 375-7. 1988.
41. **Anderson JR**, Probert KJ, Harrington DP. Guidelines for reporting outcomes of lymphoma trials. *Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology*. 6(3): 559-60. 1988.
42. Rayburn W, Harman M, Legino L, Woods R, **Anderson J**. Routine preoperative ultrasonography and cesarean section. *American Journal of Perinatology*. 5(3): 297-9. 1988.
43. Probert KJ, **Anderson JR**. Assessing the effect of toxicity on prognosis: methods of analysis and interpretation. *Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology*. 6(5): 868-70. 1988.
44. Goldhaber SZ, Parker JA, Tumei SS, Drum D, Loscalzo J, Reagan K, Selwyn AP, **Anderson J**, Braunwald E, Kessler CM, Heit J, Markis J, Sharma GV, Dawley D, Nagel JS, Kim D, Vaughan DE. A randomized controlled trial of recombinant tissue plasminogen activator versus urokinase in the treatment of acute pulmonary embolism. *Lancet*. 8606: 293-297. 1988.
45. Davis RB, **Anderson JR**. Exponential survival trees. *Statistics in Medicine*. 8(8): 947-61. 1989.
46. Kornblith AB, **Anderson J**, Cella DF, Tross S, Zuckerman E, Cherin E, Henderson ES, Weiss RB, Cooper MR, Silver RT. Quality of life assessment of Hodgkin's disease survivors: a model for cooperative clinical trials. *Oncology (Williston Park, N.Y.)*. 4(5): 93-101; di. 1990.

47. Gottlieb AJ, **Anderson JR**, Ginsberg SJ, Bloomfield CD, Norton L, Barcos M, Peterson BA, Nissen N, Henderson ES, Holland JF. A randomized comparison of methotrexate dose and the addition of bleomycin to CHOP therapy for diffuse large cell lymphoma and other non-Hodgkin's lymphomas. Cancer and Leukemia Group B study 7851. *Cancer*. 66(9): 1888-96. 1990.
48. Green MR, Kramar A, Schilsky R, Stoopler M, Zimmer B, Richards F, Skarin A, **Anderson JR**. Platinum-based combination chemotherapy in advanced non-small cell lung cancer: a randomized phase II trial of the Cancer and Leukemia Group B. *Medical and Pediatric Oncology*. 18(3): 197-202. 1990.
49. **Anderson JR**, Santarelli MT, Peterson B. Dose intensity in the treatment of diffuse large-cell lymphoma. *Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology*. 8(11): 1927-8. 1990.
50. Duggan DB, **Anderson JR**, Dillman R, Case D, Gottlieb AJ. 2 Deoxycoformycin (pentostatin) for refractory non-Hodgkin's lymphoma: a CALGB phase II study. *Medical and Pediatric Oncology*. 18(3): 203-6. 1990.
51. Schouten HC, Sanger WG, Weisenburger DD, **Anderson J**, Armitage JO. Chromosomal abnormalities in untreated patients with non-Hodgkins lymphoma: associations with histology, clinical characteristics, and treatment outcome. The Nebraska Lymphoma Study Group. *Blood*. 75(9): 1841-7. 1990.
52. Fischl MA, Richman DD, Hansen N, Collier AC, Carey JT, Para MF, Hardy WD, Dolin R, Powderly WG, Allan JD, Wong B, Merigan TC, AcAuliffe VJ, Hyslop NE, Rhame FS, Volberding P, Pettinelli C, **Anderson JR**. The safety and efficacy of zidovudine (AZT) in the treatment of subjects with mildly symptomatic human immunodeficiency virus type 1 (HIV) infection. A double-blind, placebo-controlled trial. The AIDS Clinical Trials Group. *Annals of Internal Medicine*. 112:727-737. 1990.
53. Byar DP, Schoenfeld DA, Green SB, Amato DA, Davis R, De Grutt R, Finkelstein DM, Gatsonis C, Gelber RD, Lagakos S, Lefkopoulou M, Tsiatis AA, Zelen M, Peto J, Freedman LS, Gail M, Simon R, Ellenberg SS, **Anderson JR**, Collins R, Peto R, Peto T. Design considerations for AIDS trials. *New England Journal of Medicine*. 323: 1343-1347. 1990.
54. Fischl MA, **Anderson JR**, Balfour HH. Response to letter to the editor: Treatment of mildly symptomatic human immunodeficiency virus (HIV) infection. *Annals of Internal Medicine*. 113: 635-636. 1990.
55. Armitage JO, Bierman PJ, Vose JM, **Anderson JR**, Weisenburger DD, Kessinger A, Reed EC, Vaughan WP, Coccia PF, Purtilo DT. Autologous bone marrow transplantation for patients with relapsed Hodgkin's disease. *The American Journal of Medicine*. 91(6): 605-11. 1991.
56. Woods MP, Rayburn WF, McIntosh DG, Scott JC, Smith ML, **Anderson JR**. Nalbuphine after major gynecologic surgery. Comparison of patient-controlled analgesia and intramuscular injections. *The Journal of Reproductive Medicine*. 36(9): 647-50. 1991.
57. **Anderson JR**, Crowley JJ, Propert KJ. Interpretation of survival data in clinical trials. *Oncology (Williston Park, N.Y.)*. 5(2): 104-10; di. 1991.
58. **Anderson JR**, Coccia PF. Is more better? Dose intensity in neuroblastoma. *Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology*. 9(6): 902-4. 1991.
59. Vose JM, Bierman PJ, **Anderson JR**, Weisenburger D, Moravec DF, Sorensen S, Hutchins M, Dowling MD, Howe D, Okerbloom J. CHLVPP chemotherapy with involved-field irradiation for Hodgkin's disease: favorable results with acceptable toxicity. *Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology*. 9(8) 1421-5. 1991.

60. Vose JM, Bierman PJ, **Anderson JR**, Kessinger A, Pierson J, Nelson J, Frappier B, Schmit-Pokorny K, Weisenburger DD, Armitage JO. Progressive disease after high-dose therapy and autologous transplantation for lymphoid malignancy: clinical course and patient. *Blood*. 80(8):2142-8. 1992.
61. Canellos GP, **Anderson JR**, Propert KJ, Nissen N, Cooper MR, Henderson ES, Green MR, Gottlieb A, Peterson BA. Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. *The New England Journal of Medicine*. 327(21): 1478-84. 1992.
62. Kornblith AB, **Anderson J**, Cella DF, Tross S, Zuckerman E, Cherin E, Henderson ES, Canellos GP, Kosty MP, Cooper MR. Comparison of psychosocial adaptation and sexual function of survivors of advanced Hodgkin disease treated by MOPP, ABVD, or MOPP alternating with ABVD. *Cancer*. 70(10): 2508-16. 1992.
63. Kornblith AB, **Anderson J**, Cella DF, Tross S, Zuckerman E, Cherin E, Henderson E, Weiss RB, Cooper MR, Silver RT. Hodgkin disease survivors at increased risk for problems in psychosocial adaptation. *The Cancer and Leukemia Group B. Cancer*. 70(8): 2214-24. 1992.
64. Raza A, Gezer S, **Anderson J**, Lykins J, Bennett J, Browman G, Goldberg J, Larson R, Vogler R, Preisler HD. Relationship of [3H] Ara-C incorporation and response to therapy with high-dose Ara-C in AML patients: a Leukemia Intergroup study. *Experimental Hematology*. 20(10): 1194- 200. 1992.
65. Gordon BG, Warkentin PI, Weisenburger DD, Vose JM, Sanger WG, Strandjord SE, **Anderson JR**, Verdirame JD, Bierman PJ, Armitage JO. Bone marrow transplantation for peripheral T-cell lymphoma in children and adolescents. *Blood*. 80(11): 2938-42. 1992.
66. Sisson JH, Thompson AB, **Anderson JR**, Robbins RA, Spurzem JR, Spence PR, Reed EC, Armitage JO, Vose JM, Arneson MA. Airway inflammation predicts diffuse alveolar hemorrhage during bone marrow transplantation in patients with Hodgkin disease. *The American Review of Respiratory Disease*. 146(2): 439-43. 1992.
67. Duggan DB, Santarelli MT, Zamkoff K, Lichtman S, Ellerton J, Cooper R, Poiesz B, **Anderson JR**, Bloomfield CD, Peterson BA. A phase II study of recombinant interleukin-2 with or without recombinant interferon-beta in non-Hodgkin's lymphoma. A study of the Cancer and Leukemia Group B. *Journal of Immunotherapy: Official Journal of the Society for Biological Therapy*. 12(2): 115-22. 1992.
68. Kurec AS, Threatte GA, Gottlieb AJ, Smith JR, **Anderson J**, Davey FR. Immunophenotypic subclassification of chronic lymphocytic leukaemia (CLL). *British Journal of Haematology*. 81(1): 45-51. 1992.
69. Case DC, Santarelli MT, Carey RW, **Anderson J**, Gottlieb A. Phase II trial of ifosfamide/mesna and mitoxantrone in previously treated patients with non-Hodgkin's lymphoma: cancer and leukemia group B study 8753. *Medical and Pediatric Oncology*. 20(4): 325-9. 1992.
70. Janov AJ, **Anderson J**, Cella DF, Zuckerman E, Kornblith AB, Holland JC, Kantor AF, Li FP, Henderson E, Weiss RB. Pregnancy outcome in survivors of advanced Hodgkin disease. *Cancer*. 70(3): 688-92. 1992.
71. Schilsky RL, Ratain MJ, Vokes EE, Vogelzang NJ, **Anderson J**, Peterson BA. Laboratory and clinical studies of biochemical modulation by hydroxyurea. *Seminars in Oncology*. 19(3 Suppl 9): 84-9. 1992.
72. Hargis JB, **Anderson JR**, Propert KJ, Green MR, Van Echo DA, Weiss RB. Predicting genitourinary toxicity in patients receiving cisplatin-based combination chemotherapy: a Cancer and Leukemia Group B study. *Cancer Chemotherapy and Pharmacology*. 30(4): 291-6. 1992.

73. Case DC, **Anderson J**, Ervin TJ, Gottlieb A. Phase II trial of ifosfamide and mesna in previously treated patients with non-Hodgkin's lymphoma: Cancer and Leukemia Group B study 8552. *Hematological Oncology*. 9(4-5): 189-96. 1992.
74. Gordon BG, Armitage JO, Coccia PF, Warkentin PI, Weisenburger DD, Vose JM, Sanger WG, Strandjord SE, **Anderson JR**, Verdirame JD, Bierman PJ. Peripheral T-Cell Lymphoma in Childhood and Adolescence: A Clinicopathologic Study of 22 patients. *Blood*. 80: 2938-2942. 1992.
75. Gordon BG, Warkentin PI, Weisenburger Dd, Vose JM, Sanger WG, Strandjord SE, **Anderson JR**, Verdirame JD, Bierman PJ, Armitage JO, Coccia PF. Bone Marrow Transplantation for Peripheral T-Cell Lymphoma in Children and Adolescents. *Blood*. 80: 2938-2942. 1992.
76. Vose JM, **Anderson JR**, Kessinger A, Bierman PJ, Coccia P, Reed EC, Gordon B, Armitage JO. High-dose chemotherapy and autologous hematopoietic stem-cell transplantation for aggressive non-Hodgkins lymphoma. *Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology*. 11(10): 1846-51. 1993.
77. Sandler DP, Shore DL, **Anderson JR**, Davey FR, Arthur D, Mayer RJ, Silver RT, Weiss RB, Moore JO, Schiffer CA. Cigarette smoking and risk of acute leukemia: associations with morphology and cytogenetic abnormalities in bone marrow. *Journal of the National Cancer Institute*. 85(24): 1994-2003. 1993.
78. **Anderson JR**, Roberson PK. Assessing secondary malignancy risk. *Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology*. 11(5): 1005. 1993.
79. Vose JM, Reed EC, Pippert GC, **Anderson JR**, Bierman PJ, Kessinger A, Spinolo J, Armitage JO. Mesna compared with continuous bladder irrigation as uroprotection during high-dose chemotherapy and transplantation: a randomized trial. *Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology*. 11(7): 1306-10. 1993.
80. **Anderson JR**, Armitage JO, Weisenberger DD. More on follicular lymphomas. *Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology*. 11(9): 1834-6. 1993.
81. Bridge JA, Bhatia PS, **Anderson JR**, Neff JR. Biologic and clinical significance of cytogenetic and molecular cytogenetic abnormalities in benign and malignant cartilaginous. *Cancer Genetics and Cytogenetics*. 69(2): 79-90. 1993.
82. **Anderson JR**, Vose JM, Bierman PJ, Weisenberger DD, Sanger WG, Pierson J, Bast M, Armitage JO. Clinical features and prognosis of follicular large-cell lymphoma: a report from the Nebraska Lymphoma Study Group. *Journal of Clinical Oncology: Official Journal of the American*. 11(2): 218-24. 1993.
83. Parker BA, Santarelli M, Green MR, **Anderson JR**, Cooper MR, Case D, Barcos M, Peterson BA, Gottlieb AJ. AMOPLACE treatment of intermediate-grade and high-grade malignant lymphoma: a Cancer and Leukemia Group B study. *Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology*. 11(2): 248-54. 1993.
84. **Anderson JR**, Roberson PK. Venous thrombosis and cancer. *The New England Journal of Medicine*. 328(12): 885; autho. 1993.
85. Kirshner JJ, **Anderson JR**, Parker B, Barcos M, Cooper MR, Burns LJ, Peterson BA, Gottlieb AJ. Etoposide in combination as first-line chemotherapy for advanced Hodgkin disease. A Cancer and Leukemia Group B study. *Cancer*. 71(5) 1852-6. 1993.
86. Mir R, **Anderson J**, Strauchen J, Nissen NI, Cooper MR, Rafla S, Canellos GP, Bloomfield CD, Gottlieb AJ, Peterson B. Hodgkin disease in patients 60 years of age or older. Histologic and clinical features of advanced-stage disease. The Cancer and Leukemia Group B. *Cancer*. 71(5): 1857-66. 1993.



87. **Anderson JR**, Jenkin RD, Wilson JF, Kjeldsberg CR, Sposto R, Chilcote RR, Coccia PF, Exelby PR, Siegel S, Meadows AT. Long-term follow-up of patients treated with COMP or LSA2L2 therapy for childhood non-Hodgkin's lymphoma: a report of CCG-551 from the Children's Cancer Group. *Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology*. 11(6): 1024-32. 1993.
88. Rybak ME, **Anderson J**, Kaplan R, Budman DR, Vinciguerra V, Gottlieb AJ. Phase II trial of etoposide and cisplatin in patients with refractory and relapsed non-Hodgkins lymphoma: Cancer and Leukemia Group B study 8351. *Medical and Pediatric Oncology*. 21(6): 441-5. 1993.
89. Shipp MA, Harrington DP, **Anderson JR**. A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. *New England Journal of Medicine*. 329: 987-94. 1993.
90. **Anderson JR**. NIH Consensus Development Panel on Impotence. *JAMA*. 270: 83-90. 1993.
91. Vose JM, **Anderson JR**, Bierman PJ, Bast M, Weisenburger D, Chan WC, Bishop MR, Armitage JO. Comparison of front-line chemotherapy for aggressive non-Hodgkin's lymphoma using the CAP-BOP regimens. *The Nebraska Lymphoma St. Seminars in Hematology*. 31(2 Suppl 3): 4-8. 1994.
92. Traystman MD, Schulte NA, MacDonald M, **Anderson JR**, Sanger WG. Mutation analysis for cystic fibrosis to determine carrier status in 167 sperm donors from the Nebraska Genetic Semen Bank. *Human mutation*. 4(4): 271-5. 1994.
93. Bishop MR, **Anderson JR**, Jackson JD, Bierman PJ, Reed EC, Vose JM, Armitage JO, Warkentin PI, Kessinger A. High-dose therapy and peripheral blood progenitor cell transplantation: effects of recombinant human granulocyte-macrophage colony-stimulating factor on the autograph. *Blood*. 83(2): 610-6. 1994.
94. Olson CE, Porter TR, Deligonul U, Xie F, **Anderson JR**. Left ventricular volume changes during Dobutamine stress echocardiography identify patients with more extensive coronary artery. *Journal of the American College of Cardiology*. 24(5): 1268-73. 1994.
95. Finlay JL, **Anderson JR**, Cecalupo AJ, Hutchinson RJ, Kadin ME, Kjeldsberg CR, Provisor AJ, Woods WG, Meadows AT. Disseminated nonlymphoblastic lymphoma of childhood: a Children's Cancer Group study, CCG-552. *Medical and Pediatric Oncology*. 23(6): 453-63. 1994.
96. **Anderson JR**, Vose J, Kessinger A. Myelodysplastic syndrome after autologous transplant for lymphoma. *Blood*. 84(11): 3988-9. 1994.
97. Birt DF, Pelling JC, **Anderson J**, Barnett T. Consumption of reduced-energy/low-fat diet or constant-energy/high-fat diet during mezerein treatment inhibited mouse skin tumor promotion. *Carcinogenesis*. 15(10): 2341-5. 1994.
98. Darrington DL, Vose JM, **Anderson JR**, Bierman PJ, Bishop MR, Chan WC, Morris ME, Reed EC, Sanger WG, Tarantolo SR. Incidence and characterization of secondary myelodysplastic syndrome and acute myelogenous leukemia following high-dose chemorad. *Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology*. 12(12): 2527-34. 1994.
99. Birt DF, Copenhaver J, Pelling JC, **Anderson J**. Dietary energy restriction and fat modulation of protein kinase C isoenzymes and phorbol ester binding in Sencar mouse epidermis. *Carcinogenesis*. 15(12): 2727-32. 1994.
100. Tempero M, **Anderson J**. Progress in colon cancer: do molecular markers matter? *New England Journal of Medicine*. 331(4): 267-8. 1994.
101. Bobo JK, Thapa PB, **Anderson JR**, Gale JL. Acute encephalopathy and seizure rates in children under age two years in Oregon and Washington state. *American Journal of Epidemiology*. 140(1): 27-38. 1994.

102. Sisson JH, Reed EC, Robbins RA, **Anderson JR**, Ogren FP, Diamond JS, Rennard SI. Impairment of nasal mucociliary clearance during bone marrow transplantation. University of Nebraska Medical Center bone Marrow. *Bone Marrow Transplantation*. 13(5): 631-3. 1994.
103. Ozer H, **Anderson JR**, Peterson BA, Budman DR, Cooper MR, Kennedy BJ, Silver RT, Henderson ES, Duggan DB, Barcos M. Combination trial of subcutaneous recombinant alpha 2 b interferon and oral cyclophosphamide in follicular low-grade non-Hodgkin's lymphoma. *Medical and Pediatric Oncology*. 22(4): 228-35. 1994.
104. Nesbit ME, Buckley JD, Feig SA, **Anderson JR**, Lampkin B, Bernstein ID, Kim TH, Piomelli S, Kersey JH, Coccia PF. Chemotherapy for induction of remission of childhood acute myeloid leukemia followed by marrow transplantation or multiagent chemotherapy: a report from the Children's Cancer Group. *Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology*. 12(1): 127-35. 1994.
105. Tempero M, Berg A, Block M, Hutchins M, Langdon R, Moravec D, Tweedy C, **Anderson J**. A Phase II Trial of protracted therapy with 5-fluorouracil and daily oral leucovorin in metastatic colorectal cancer. *Journal of Infusional Chemotherapy*. 4: 112-115. 1994.
106. Ozer H, Miller LL, **Anderson JR**. American Society of Clinical Oncology. Recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. *Journal of Clinical Oncology*. 12: 2471-2508. 1994.
107. Gmeiner WH, **Anderson J**, Sahasrabudhe P. NMR studies show monomeric 5-fluorouridine forms base pairs for increased stability compared with uridine in non-aqueous solvents. *Nucleosides and Nucleotides*. 13: 2329-2344. 1994.
108. **Anderson JR**, Strickland D, Corbin D, Byrnes JA, Zweiback E. Age-specific reference ranges for serum prostate-specific antigen. *Urology*. 46(1): 54-7. 1995.
109. Kessinger A, Bishop MR, **Anderson JR**, Armitage JO, Bierman PJ, Reed EC, Tarantolo S, Tempero MA, Vose JM, Warkentin PI. Comparison of subcutaneous and intravenous administration of recombinant human granulocyte-macrophage colony-stimulating factor. *Journal of Hematotherapy*. 4(2): 81-4. 1995.
110. Stewart DA, Vose JM, Weisenburger DD, **Anderson JR**, Ruby EI, Bast MA, Bierman PJ, Kessinger A, Armitage JO. The role of high-dose therapy and autologous hematopoietic stem cell transplantation for mantle cell lymphoma. *Annals of Oncology*. 6(3): 263-6. 1995.
111. Bennett CL, Armitage JL, Armitage GO, Vose JM, Bierman PJ, Armitage JO, **Anderson JR**. Costs of care and outcomes for high-dose therapy and autologous transplantation for lymphoid malignancies: results from the University of Nebraska 1987 through 1991. *Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology*. 13(4): 969-73. 1995.
112. Yan Y, Chan WC, Weisenburger DD, **Anderson JR**, Bast MA, Vose JM, Bierman PJ, Armitage JO. Clinical and prognostic significance of bone marrow involvement in patients with diffuse aggressive B-cell lymphoma. *Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology*. 13(6): 1336-42. 1995.
113. Martin AR, Weisenburger DD, Chan WC, Ruby EI, **Anderson JR**, Vose JM, Bierman PJ, Bast MA, Daley DT, Armitage JO. Prognostic value of cellular proliferation and histologic grade in follicular lymphoma. *Blood*. 85(12): 3671-8. 1995.
114. Porter TR, Xie F, **Anderson JR**, Kricsfeld A, D'Sa A. Multifold sonicated dilutions of albumin with fifty percent dextrose improve left ventricular contrast videointensity after intr. *Journal of the American Society of Echocardiography*. 7(5) : 465-71. 1995.

115. Martin-Algarra S, Bishop MR, Tarantolo S, Cowles MK, Reed E, **Anderson JR**, Vose JM, Bierman P, Armitage JO, Kessinger A. Hematopoietic growth factors after HLA-identical allogeneic bone marrow transplantation in patients treated with methotrexate-co. *Experimental Hematology*. 23(14): 1503-8. 1995.
116. **Anderson JR**, Armitage JO, Vose JM, Bierman PJ, Weisenburger DD, Cunningham D, Mead GM, Whitehouse JM, Proctor SJ. CHLVPP therapy for Hodgkin's disease: Experience of 960 patients. *Annals of Oncology*. 6: 167-172. 1995.
117. **Anderson JR**, Jameton A, Reitemeier PJ, Prentice E. The Case of Two Devices: Is Disclosure to Subjects Required Following the Discovery of Phase IV ("Post Marketing") Research in Which Subjects Were Not Informed That They Were Participants?" IRB: A Review of Human Subjects Research. 1995.
118. Piira T, Perkins SL, **Anderson JR**, Meadows AT, Chilcote RR, Kadin M, Kjeldsberg CR. Primary mediastinal large cell lymphoma in children: a report from the Childrens Cancer Group. *Pediatric Pathology & Laboratory Medicine: Journal of the Society for Pediatric Pathology, affiliated with the International Paediatric Pathology Association*. 15(4): 561-70. 1996.
119. Weisenburger DD, Gordon BG, Vose JM, Bast MA, Chan WC, Greiner TC, **Anderson JR**, Sanger WG. Occurrence of the t(2;5)(p23;q35) in non-Hodgkin's lymphoma. *Blood*. 87(9): 3860-8. 1996.
120. Evans AE, **Anderson JR**, Lefkowitz-Boudreaux IB, Finlay JL. Adjuvant chemotherapy of childhood posterior fossa ependymoma: cranio-spinal irradiation with or without adjuvant CCNU, vincristine, and prednisone: a Children's Cancer Group study. *Medical and Pediatric Oncology*. 27(1): 8-14. 1996.
121. Vose JM, Anderson JE, Bierman PJ, Appelbaum FR, **Anderson JR**, Garrison L, Lebsack ME, Armitage JO. Phase I/II trial of PIXY321 to enhance engraftment following autologous bone marrow transplantation for lymphoid malignancy. *Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology*. 14(2): 520-6. 1996.
122. Greiner TC, Moynihan MJ, Chan WC, Lytle DM, Pedersen A, **Anderson JR**, Weisenburger DD. p53 mutations in mantle cell lymphoma are associated with variant cytology and predict a poor prognosis. *Blood*. 87(10): 4302-10. 1996.
123. Jain B, Floreani AA, **Anderson JR**, Vose JM, Robbins RA, Rennard SI, Sisson JH. Cardiopulmonary function and autologous bone marrow transplantation: results and predictive value for respiratory failure and mo. *Bone Marrow Transplantation*. 17(4):561-8. 1996.
124. Bierman PJ, **Anderson JR**, Freeman MB, Vose JM, Kessinger A, Bishop MR, Armitage JO. High- dose chemotherapy followed by autologous hematopoietic rescue for Hodgkin's disease patients following first relapse after c. *Annals of Oncology*. 7(2): 151-6. 1996.
125. Vose JM, Bierman PJ, **Anderson JR**, Harrison KA, Dalrymple GV, Byar K, Kessinger A, Armitage JO. Single-photon emission computed tomography gallium imaging versus computed tomography: predictive value in patients undergoing high-dose chemotherapy and autologous stem-cell transplantation for non-Hodgkin's lymphoma. *Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology*. 14(9): 2473-9. 1996.
126. Smir BN, Hauke RJ, Bierman PJ, Gross TG, d'Amore F, **Anderson JR**, Greiner TC. Molecular epidemiology of deletions and mutations of the latent membrane protein 1 oncogene of the Epstein-Barr virus in posttra. *Laboratory Investigation*. 75(4): 575-88. 1996.

127. Bishop MR, Henslee-Downey PJ, **Anderson JR**, Romond EH, Marciniak E, Yankey R, Reeves M, Thompson JS. Long-term survival in advanced chronic myelogenous leukemia following bone marrow transplantation from haploidentical related donors. *Bone Marrow Transplantation*. 18(4): 747-53. 1996.
128. **Anderson JR**, Jameton A, Reitemeier PJ, Prentice E. The case of two devices: disclosure to subjects following Phase IV (post-marketing) research. *IRB*. 17(3): 6-9. 1996.
129. Darrington DL, Vose JM, **Anderson JR**, et al. Incidence and characterization of secondary myelodysplastic syndrome and acute myelogenous leukemias following high-dose chemoradiotherapy and autologous stem-cell transplantation for lymphoid malignancies. *Classic Papers and Current Comments*. 1: 406-414. 1996.
130. Bobo JK, **Anderson JR**, Bowman A. Training chemical dependency counselors to treat nicotine dependence. *Addictive Behaviors*. 22(1): 23-30. 1997.
131. Bierman PJ, Vose JM, Anderson JR, Bishop MR, Kessinger A, Armitage JO. High-dose therapy with autologous hematopoietic rescue for follicular low-grade non-Hodgkin's lymphoma. *Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology*. 15(2): 445-50. 1997.
132. Raney RB, Asmar L, Newton WA, Bagwell C, Breneman JC, Crist W, Gehan EA, Webber B, Wharam M, Wiener ES, **Anderson JR**, Maurer HM. Ewing's sarcoma of soft tissues in childhood: a report from the Intergroup Rhabdomyosarcoma Study, 1972 to 1991. *Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology*. 15(2): 574-82. 1997.
133. Smir BN, Hauke RJ, Bierman PJ, Gross TG, d'Amore F, **Anderson JR**, Greiner TC. Molecular epidemiology of deletions and mutations of the latent membrane protein 1 oncogene of the Epstein-Barr virus in posttransplant lymphoproliferative disorders. *Laboratory Investigation*. 76(3): 439. 1997.
134. Donaldson SS, **Anderson J**. Factors that influence treatment decisions in childhood rhabdomyosarcoma. Intergroup Rhabdomyosarcoma Study Group of the Children's Cancer Group, the Pediatric Oncology Group, and the Intergroup Rhabdomyosarcoma Study Group Statistical Center. *Radiology*. 203(1): 17-22. 1997.
135. Arndt C, Tefft M, Gehan E, **Anderson J**, Jenson M, Link M, Donaldson S, Breneman J, Wiener E, Webber B, Maurer H. A feasibility, toxicity, and early response study of etoposide, ifosfamide, and vincristine for the treatment of children with rhabdomyosarcoma: a report from the Intergroup Rhabdomyosarcoma Study (IRS) IV pilot study. *Journal of Pediatric Hematology/Oncology*. 19(2): 124-9. 1997.
136. Tempero M, Lechner P, Dalrymple G, Harrison K, Augustine S, Schlam J, **Anderson J**, Wisecarver J, Colcher D. High-dose therapy with iodine-131-labeled monoclonal antibody CC49 in patients with gastrointestinal cancers: a phase I trial. *Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology*. 15(4): 1518-28. 1997.
137. Bishop MR, Tarantolo SR, Jackson JD, **Anderson JR**, Schmit-Pokorny K, Zacharias D, Pavletic ZS, Pirruccello SJ, Vose JM, Bierman PJ, Warkentin PI, Armitage JO, Kessinger A. Allogeneic- blood stem-cell collection following mobilization with low-dose granulocyte colony-stimulating factor. *Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology*. 15(4): 1601-7. 1997.
138. Lawrence W, **Anderson JR**, Gehan EA, Maurer H. Pretreatment TNM staging of childhood rhabdomyosarcoma: a report of the Intergroup Rhabdomyosarcoma Study Group. Children's Cancer Study Group. *Pediatric Oncology Group. Cancer*. 80(6):1165-70. 1997.

139. **Anderson JR**. A clinical evaluation of the International Lymphoma Study Group classification of on-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project. *Blood*. 89: 33909-3918. 1997.
140. **Anderson JR**. Effect of age on the characteristics and clinical behavior of non-Hodgkin's lymphoma patients. The Non-Hodgkin's Lymphoma Classification Project. *Ann Oncol*. 8: 973-978. 1997.
141. Peters C, Shapiro EG, **Anderson J**, Henslee-Downey PJ, Klemperer MR, Cowan MJ, Saunders EF, deAlarcon PA, Twist C, Nachman JB, Hale GA, Harris RE, Rozans MK, Kurtzberg J, Grayson GH, Williams TE, Lenarsky C, Wagner JE, Krivit W. Hurler syndrome: II. Outcome of HLA-genotypically identical sibling and HLA-haploidentical related donor bone marrow transplantation in fifty-four children. The Storage Disease Collaborative Study Group. *Blood*. 91(7): 2601-8. 1998.
142. Coleman M, Rafla S, Propert KJ, Glicksman A, Peterson B, Nissen N, Brunner K, Holland JF, **Anderson JR**, Gottlieb A, Kaufman T. Augmented therapy of extensive Hodgkins disease: radiation to known disease or prolongation of induction chemotherapy did not improve survival--results of a Cancer and Leukemia Group B study. *International Journal of Radiation Oncology, Biology, Physics*. 41(3): 639-45. 1998.
143. Casale GP, Scott DM, **Anderson JR**, Vitzthum EF, Gold RE. A preliminary study of immunologic and hematologic profiles of peripheral blood from Nebraska farmers who apply pesticides to their fields. *Journal of Toxicology Clinical Toxicology*. 36(3): 183-94. 1998.
144. **Anderson JR**, Armitage JO, Weisenburger DD. Epidemiology of the non-Hodgkin's lymphomas: distributions of the major subtypes differ by geographic locations. *Non-Hodgkin's Lymphomas. Annals of oncology*. 9(7): 717-20. 1998.
145. Knowles KI, Ibarrola JL, Ludlow MO, **Anderson JR**, Newcomb BE. Rubber latex allergy and the endodontic patient. *Journal of Endodontics*. 24(11): 760-2. 1998.
146. **Anderson JR**. Immunization against Lyme disease. *The New England Journal of Medicine*. 339(22): 1638-9. 1998.
147. Diebold J, Weisenburger D, MacLennan KA, Müller-Hermelink HK, Nathwani BN, Harris NL, **Anderson JR**, Roy P, Armitage JO. [Reproducibility and prognostic value of histopathological classifications of malignant lymphomas. Prolegomena for the 1<sup>st</sup> international classification proposed by WHO. Group of the non-Hodgkin's Malignant Lymphoma Classification Project]. *Bulletin de l'Académie nationale de médecine*. 182(7): 1537-48; d. 1998.
148. Kessinger A, Bierman PJ, Cowles MK, **Anderson JR**, Armitage JO, Bishop MR, Vose JM. Mobilized versus non-mobilized peripheral stem cell transplantation after high dose therapy for low grade non-Hodgkin's lymphoma: Effect on failure-free survival. *Cancer Research Therapy and Control*. 5: 113-119. 1998.
149. Smith MA, Rubinstein L, **Anderson JR**, Arthur D, Catalano PJ, Freidlin B, Heyn R, Khayat A, Krailo M, Land VJ, Miser J, Shuster J, Vena D. Secondary leukemia or myelodysplastic syndrome after treatment with epipodophyllotoxins. *Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology*. 17(2): 569-77. 1999.
150. Nathwani BN, **Anderson JR**, Armitage JO, Cavalli F, Diebold J, Drachenberg MR, Harris NL, MacLennan KA, Müller-Hermelink HK, Ullrich FA, Weisenburger DD. Clinical significance of follicular lymphoma with monocytoid B cells. Non-Hodgkins Lymphoma Classification Project. *Human Pathology*. 30(3): 263-8. 1999.

151. Beech TR, Moss RL, **Anderson JA**, Maurer HM, Qualman SJ, Breneman JC, Wiener ES, Crist WM. What comprises appropriate therapy for children/adolescents with rhabdomyosarcoma arising in the abdominal wall? A report from the Intergroup Rhabdomyosarcoma Study Group. *Journal of Pediatric Surgery*. 34(5): 668-71. 1999.
152. Blakely ML, Lobe TE, **Anderson JR**, Donaldson SS, Andrassy RJ, Parham DM, Wharam MD, Qualman SJ, Wiener ES, Grier HE, Crist WM. Does debulking improve survival rate in advanced-stage retroperitoneal embryonal rhabdomyosarcoma? *Journal of Pediatric Surgery*. 34(5): 736-41; di. 1999.
153. Chiou RK, Alberts GL, Pomeroy BD, Anderson JC, Carlson LK, **Anderson JR**, Wobig RK. Study of cavernosal arterial anatomy using color and power Doppler sonography: impact on hemodynamic parameter measurement. *The Journal of Urology*. 162(2): 358-60. 1999.
154. **Anderson JR**, Harrington D. Re: The management of interim analyses in drug development by Karen M. Facey and John A. Lewis, *Statistics in Medicine*, 17, 1801-1809 (1998). *Statistics in Medicine*. 18(15): 2063-5. 1999.
155. Silver RT, Woolf SH, Hehlmann R, Appelbaum FR, **Anderson J**, Bennett C, Goldman JM, Guilhot F, Kantarjian HM, Lichtin AE, Talpaz M, Tura S. An evidence-based analysis of the effect of busulfan, hydroxyurea, interferon, and allogeneic bone marrow transplantation in treating the chronic phase of chronic myeloid leukemia: developed for the American Society of Hematology. *Blood*. 94(5): 1517-36. 1999.
156. Freeman M, Vose J, Bennett C, **Anderson J**, Kessinger A, Turner K, Pierson J, Bishop M, Bierman P, Armitage J. Costs of care associated with high-dose therapy and autologous transplantation for non-Hodgkin's lymphoma: results from the University of Nebraska Medical Center 1989 to 1995. *Bone Marrow Transplantation*. 24(6): 679-84. 1999.
157. Raney RB, Asmar L, Vassilopoulou-Sellin R, Klein MJ, Donaldson SS, Green J, Heyn R, Wharam M, Glicksman AS, Gehan EA, **Anderson J**, Maurer HM. Late complications of therapy in 213 children with localized, non-orbital soft-tissue sarcoma of the head and neck: A descriptive report from the Intergroup Rhabdomyosarcoma Studies (IRS)-II and - III. IRS Group of the Children's Cancer Group and the Pediatric Oncology Group. *Medical and Pediatric Oncology*. 33(4): 362-71. 1999.
158. Wolden SL, **Anderson JR**, Crist WM, Breneman JC, Wharam MD, Wiener ES, Qualman SJ, Donaldson SS. Indications for radiotherapy and chemotherapy after complete resection in rhabdomyosarcoma: A report from the Intergroup Rhabdomyosarcoma Studies I to III. *Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology*. 17(11): 3468-75. 1999.
159. Pappo AS, **Anderson JR**, Crist WM, Wharam MD, Breitfeld PP, Hawkins D, Raney RB, Womer RB, Parham DM, Qualman SJ, Grier HE. Survival after relapse in children and adolescents with rhabdomyosarcoma: A report from the Intergroup Rhabdomyosarcoma Study Group. *Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology*. 17(11): 3487-93. 1999.
160. Nathwani BN, **Anderson JR**, Armitage JO, Cavalli F, Diebold J, Drachenberg MR, Harris NL, MacLennan KA, Müller-Hermelink HK, Ullrich FA, Weisenburger DD. Marginal zone B-cell lymphoma: A clinical comparison of nodal and mucosa-associated lymphoid tissue types. Non-Hodgkins Lymphoma Classification Project. *Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology*. 17(8): 2486-92. 1999.

161. Andrassy RL, Wiener ES, Raney RB, Hays DM, Arndt CAS, Lobe TE, Lawrence W, **Anderson JR**, Qualman SJ, Crist WM. Progress in Surgical management of vaginal RMS: A 25-year review from the IRS committee. *Journal of Pediatric Surgery*. 34: 731-735. 1999.
162. Spunt SL, Lobe TE, Pappo AS, Parham DM, Wharam MD, Arndt C, **Anderson JR**, Crist WM, Paidas C, Wiener E, Andrassy RJ, Schwartz CL. Aggressive surgery is unwarranted for biliary tract rhabdomyosarcoma. *Journal of Pediatric Surgery*. 35(2):309-16. 2000.
163. Neville HL, Andrassy RJ, Lobe TE, Bagwell CE, **Anderson JR**, Womer RB, Crist WM, Wiener ES. Preoperative staging, prognostic factors, and outcome for extremity rhabdomyosarcoma: a preliminary report from the Intergroup Rhabdomyosarcoma Study IV (1991-1997). *Journal of Pediatric Surgery*. 35(2): 317-21. 2000.
164. Raney RB, **Anderson JR**, Kollath J, Vassilopoulou-Sellin R, Klein MJ, Heyn R, Glicksman AS, Wharam M, Crist WM, Maurer HM. Late effects of therapy in 94 patients with localized rhabdomyosarcoma of the orbit: Report from the Intergroup Rhabdomyosarcoma Study (IRS)-III, 1984-1991. *Medical and Pediatric Oncology*. 34(6): 413-20. 2000.
165. Baker KS, **Anderson JR**, Link MP, Grier HE, Qualman SJ, Maurer HM, Breneman JC, Wiener ES, Crist WM. Benefit of intensified therapy for patients with local or regional embryonal rhabdomyosarcoma: results from the Intergroup Rhabdomyosarcoma Study IV. *Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology*. 18(12): 2427-34. 2000.
166. Greiner TC, Abou-Ellella AA, Smir BN, Orazi A, Hinrichs S, **Anderson J**, Gross T, Bierman P, Hauke R. Molecular epidemiology of EBNA-1 substrains of Epstein-Barr virus in post-transplant lymphoproliferative disorders which have infrequent p53 mutations. *Leukemia & Lymphoma*. 38(5-6): 563-76. 2000.
167. Tempero M, Leichner P, Baranowska-Kortylewicz J, Harrison K, Augustine S, Schlom J, **Anderson J**, Wisecarver J, Colcher D. High-dose therapy with 90Yttrium-labeled monoclonal antibody CC49: a phase I trial. *Clinical Cancer Research*. 6(8): 3095-102. 2000.
168. Raney RB, **Anderson JR**, Andrassy RJ, Crist WM, Donaldson SS, Maurer HM, Maurer HM. Soft-tissue sarcomas of the diaphragm: a report from the Intergroup Rhabdomyosarcoma Study Group from 1972 to 1997. *Journal of Pediatric Hematology/Oncology*. 22(6): 510-4. 2000.
169. **Anderson JR**, Ellis RW, Blankenau RJ, Beiraghi SM, Westerman GH. Caries resistance in enamel by laser irradiation and topical fluoride treatment. *Journal of Clinical Laser Medicine & Surgery*. 18(1): 33-6. 2000.
170. Gordon BG, Prentice ED, **Anderson JR**. Case study: conflict between research design and minimization of risks in pediatric research. *IRB: Rev Human Subjects Res*. 22(3): 1-3. 2000.
171. Oberlin O, Rey A, **Anderson J**, Carli M, Raney RB, Treuner J, Stevens MC, Stevens MC. Treatment of orbital rhabdomyosarcoma: survival and late effects of treatment--results of an international workshop. *Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology*. 19(1): 197-204. 2001.
172. Kobrinsky NL, Sposto R, Shah NR, **Anderson JR**, DeLaat C, Morse M, Warkentin P, Gilchrist GS, Cohen MD, Shina D, Meadows AT. Outcomes of treatment of children and adolescents with recurrent non-Hodgkin's lymphoma and Hodgkin's disease with dexamethasone, etoposide, cisplatin, cytarabine, and l-asparaginase, maintenance chemotherapy, and transplantation: Childrens Cancer Group Stu. *Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology*. 19(9): 2390-6. 2001.

173. Weisenburger DD, **Anderson JR**, Diebold J, Gascoyne RD, MacLennan KA, MÅ¼ller-Hermelin HK, Nathwani BN, Ullrich F, Armitage JO. Systemic anaplastic large-cell lymphoma: results from the non-Hodgkins lymphoma classification project. *American Journal of Hematology*. 67(3): 172-8. 2001.
174. Hawkins DS, **Anderson JR**, Paidas CN, Wharam MD, Qualman SJ, Pappo AS, Scott Baker K, Crist WM. Improved outcome for patients with middle ear rhabdomyosarcoma: a childrens oncology group study. *Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology*. 19(12): 3073-9. 2001.
175. Crist WM, **Anderson JR**, Meza JL, Fryer C, Raney RB, Ruymann FB, Breneman J, Qualman SJ, Wiener E, Wharam M, Lobe T, Webber B, Maurer HM, Donaldson SS. Intergroup rhabdomyosarcoma study-IV: results for patients with non-metastatic disease. *Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology*. 19(12): 3091-102. 2001.
176. Arndt CA, Donaldson SS, **Anderson JR**, Andrassy RJ, Laurie F, Link MP, Raney RB, Maurer HM, Crist WM. What constitutes optimal therapy for patients with rhabdomyosarcoma of the female genital tract? *Cancer*. 91(12): 2454-68. 2001.
177. Spunt SL, **Anderson JR**, Teot LA, Breneman JC, Meyer WH, Pappo AS, Pappo AS. Routine brain imaging is unwarranted in asymptomatic patients with rhabdomyosarcoma arising outside of the head and neck region that is metastatic at diagnosis: a report from the Intergroup Rhabdomyosarcoma Study Group. *Cancer*. 92(1): 121-5. 2001.
178. Wiener ES, **Anderson JR**, Ojimba JI, Lobe TE, Paidas C, Andrassy RJ, Raney RB, Qualman SJ, Donaldson SS, Maurer HM, Link MP, Crist WM, Grier HE. Controversies in the management of paratesticular rhabdomyosarcoma: is staging retroperitoneal lymph node dissection necessary for adolescents with resected paratesticular rhabdomyosarcoma? *Seminars in Pediatric Surgery*. 10(3): 146-52. 2001.
179. Hauke R, Smir B, Greiner T, Bierman P, Tarantolo S, **Anderson J**, Shaw B, Armitage J. Clinical and pathological features of posttransplant lymphoproliferative disorders: influence on survival and response to treatment. *Annals of Oncology*. 12(6): 831-4. 2001.
180. Lin MF, Lee MS, Zhou XW, Andressen JC, Meng TC, Johansson SL, West WW, Taylor RJ, **Anderson JR**, Lin FF. Decreased expression of cellular prostatic acid phosphatase increases tumorigenicity of human prostate cancer cells. *The Journal of Urology*. 166(5): 1943-50. 2001.
181. Smith LM, **Anderson JR**, Qualman SJ, Crist WM, Paidas CN, Teot LA, Pappo AS, Link MP, Grier HE, Wiener ES, Breneman JC, Raney RB, Maurer HM, Donaldson SS. Which patients with microscopic disease and rhabdomyosarcoma experience relapse after therapy? A report from the soft tissue sarcoma committee of the childrens oncology group. *Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology*. 19(20): 4058-64. 2001.
182. Gordon B, Prentice E, **Anderson J**. Conflict between research design and minimization of risks in pediatric research. *IRB*. 22(3): 1-6. 2001.
183. Walterhouse DO, Pappo AS, Baker KS, Parham DM, **Anderson JR**, Donaldson SS, Paidas CN, Womer RB, Crist WM. Rhabdomyosarcoma of the parotid region occurring in childhood and adolescence. A report from the Intergroup Rhabdomyosarcoma Study Group. *Cancer*. 92(12): 3135-46. 2001.



184. Raney RB, **Anderson JR**, Barr FG, Donaldson SS, Pappo AS, Qualman SJ, Wiener ES, Maurer HM, Crist WM. Rhabdomyosarcoma and undifferentiated sarcoma in the first two decades of life: a selective review of intergroup rhabdomyosarcoma study group experience and rationale for Intergroup Rhabdomyosarcoma Study V. *Journal of Pediatric Hematology/Oncology*. 23(4): 215-20. 2001.
185. Raney RB, Maurer HM, **Anderson JR**, Andrassy RJ, Donaldson SS, Qualman SJ, Wharam MD, Wiener ES, Crist WM. The Intergroup Rhabdomyosarcoma Study Group (IRSG): Major Lessons From the IRS-I Through IRS-IV Studies as Background for the Current IRS-V Treatment Protocols. *Sarcoma*. 5(1): 9-15. 2001.
186. Raney RB, Meza J, **Anderson JR**, Fryer CJ, Donaldson SS, Breneman JC, Fitzgerald TJ, Gehan EA, Michalski JM, Ortega JA, Qualman SJ, Sandler E, Wharam MD, Wiener ES, Maurer HM, Crist WM. Treatment of children and adolescents with localized parameningeal sarcoma: experience of the Intergroup Rhabdomyosarcoma Study Group protocols IRS-II through -IV, 1978-1997. *Medical and Pediatric Oncology*. 38(1): 22-32. 2002.
187. Rüdiger T, Weisenburger DD, **Anderson JR**, Armitage JO, Diebold J, MacLennan KA, Nathwani BN, Ullrich F, Müller-Hermelink HK, Müller-Hermelink HK. Peripheral T-cell lymphoma (excluding anaplastic large-cell lymphoma): results from the Non-Hodgkin's Lymphoma Classification Project. *Annals of Oncology*. 13(1): 140-9. 2002.
188. Diebold J, **Anderson JR**, Armitage JO, Connors JM, MacLennan KA, Müller-Hermelink HK, Nathwani BN, Ullrich F, Weisenburger DD. Diffuse large B-cell lymphoma: a clinicopathologic analysis of 444 cases classified according to the updated Kiel classification. *Leukemia & Lymphoma*. 43(1): 97-104. 2002.
189. Smith LM, **Anderson JR**, Coffin CM. Cytodifferentiation and clinical outcome after chemotherapy and radiation therapy for rhabdomyosarcoma (RMS). *Medical and Pediatric Oncology*. 38(6): 398-404. 2002.
190. Newland MC, Ellis SJ, Lydiatt CA, Peters KR, Tinker JH, Romberger DJ, Ullrich FA, **Anderson JR**. Anesthetic-related cardiac arrest and its mortality: a report covering 72,959 anesthetics over 10 years from a US teaching hospital. *Anesthesiology*. 97(1):108-15. 2002.
191. Swindells S, Cobos DG, Lee N, Lien EA, Fitzgerald AP, Pauls JS, **Anderson JR**. Racial/ethnic differences in CD4 T cell count and viral load at presentation for medical care and in follow-up after HIV-1 infec. *AIDS (London, England)*. 16(13): 1832-4. 2002.
192. Muellemann RL, DenOtter T, Wadman MC, Tran TP, **Anderson J**. Problem gambling in the partner of the emergency department patient as a risk factor for intimate partner violence. *The Journal of Emergency Medicine*. 23(3): 307-12. 2002.
193. Baker KS, **Anderson JR**, Lobe TE, Wharam MD, Qualman SJ, Raney RB, Ruymann FB, Womer RB, Meyer WH, Link MP, Crist WM. Children from ethnic minorities have benefited equally as other children from contemporary therapy for rhabdomyosarcoma: a report from the Intergroup Rhabdomyosarcoma Study Group. *Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology*. 20(22): 4428-33. 2002.
194. Rennard SI, Umino T, Millatmal T, Daughton DM, Manouilova LS, Ullrich FA, Patil KD, Romberger DJ, Floreani AA, **Anderson JR**. Evaluation of subclinical respiratory tract inflammation in heavy smokers who switch to a cigarette-like nicotine delivery device that primarily heats tobacco. *Nicotine & Tobacco Research*. 4(4): 467-76. 2002.

195. Breneman JC, Lyden E, Pappo AS, Link MP, **Anderson JR**, Parham DM, Qualman SJ, Wharam MD, Donaldson SS, Maurer HM, Meyer WH, Baker KS, Paidas CN, Crist WM. Prognostic factors and clinical outcomes in children and adolescents with metastatic rhabdomyosarcoma--a report from the Intergroup Rhabdomyosarcoma Study IV. *Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology*. 21(1): 78-84. 2003.
196. Cairo MS, Sposto R, Hoover-Regan M, Meadows AT, **Anderson JR**, Siegel SE, Kadin ME, Kjeldsberg CR, Wilson JF, Perkins SL, Lones MA, Morris E, Finlay JL. Childhood and adolescent large-cell lymphoma (LCL): a review of the Children's Cancer Group experience. *American Journal of Hematology*. 72(1): 53-63. 2003.
197. Cairo MS, Sposto R, Perkins SL, Meadows AT, Hoover-Regan ML, **Anderson JR**, Siegel SE, Lones MA, Tedeschi-Blok N, Kadin ME, Kjeldsberg CR, Wilson JF, Sanger W, Morris E, Krailo MD, Finlay JL. Burkitts and Burkitt-like lymphoma in children and adolescents: a review of the Childrens Cancer Group experience. *British Journal of Haematology*. 120(4): 660-70. 2003.
198. Blakely ML, Andrassy RJ, Raney RB, **Anderson JR**, Wiener ES, Rodeberg DA, Paidas CN, Lobe TE, Crist WM, Crist WM. Prognostic factors and surgical treatment guidelines for children with rhabdomyosarcoma of the perineum or anus: a report of Intergroup Rhabdomyosarcoma Studies I through IV, 1972 through 1997. *Journal of Pediatric Surgery*. 38(3): 347-53. 2003.
199. Luo X, Carlson KA, Wojna V, Mayo R, Biskup TM, Stoner J, **Anderson J**, Gendelman HE, Meléndez LM. Macrophage proteomic fingerprinting predicts HIV-1-associated cognitive impairment. *Neurology*. 60(12): 1931-7. 2003.
200. **Anderson JR**, Schonfeld TL, Kelso TK, Prentice ED. Women in early phase trials: an IRBs deliberations. *IRB*. 25(4): 7-11. 2003.
201. Joshi D, **Anderson JR**, Paidas C, Breneman J, Parham DM, Crist W, Crist W. Age is an independent prognostic factor in rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Childrens Oncology Group. *Pediatric Blood & Cancer*. 42(1): 64-73. 2004.
202. Sung L, **Anderson JR**, Arndt C, Raney RB, Meyer WH, Pappo AS. Neurofibromatosis in children with Rhabdomyosarcoma: a report from the Intergroup Rhabdomyosarcoma study IV. *The Journal of Pediatrics*. 144(5): 666-8. 2004.
203. Arndt C, Hawkins D, **Anderson JR**, Breitfeld P, Womer R, Meyer W. Age is a risk factor for chemotherapy-induced hepatopathy with vincristine, dactinomycin, and cyclophosphamide. *Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology*. 22(10): 1894-901. 2004.
204. **Anderson JR**, Meyer WH, Wiener ES. Favorable outcome for children with paratesticular alveolar histology rhabdomyosarcoma. *Pediatric Blood & Cancer*. 43(2): 180. 2004.
205. Sung L, **Anderson JR**, Donaldson SS, Spunt SL, Crist WM, Pappo AS, Pappo AS. Late events occurring five years or more after successful therapy for childhood rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Childrens Oncology Group. *European Journal of Cancer (Oxford, England: 1990)*. 40(12): 1878-85. 2004.
206. Spunt SL, Smith LM, Ruyman FB, Qualman SJ, Donaldson SS, Rodeberg DA, **Anderson JR**, Crist WM, Link MP. Cyclophosphamide dose intensification during induction therapy for intermediate-risk pediatric rhabdomyosarcoma is feasible but does not improve outcome: a report from the soft tissue sarcoma committee of the children's Oncology Group. *Clinical Cancer Research: an Official Journal of the American Association for Cancer Research*. 10(18 Pt 1): 6072-9. 2004.

207. Rupp ME, Fitzgerald T, Marion N, Helget V, Puumala S, **Anderson JR**, Fey PD. Effect of silver-coated urinary catheters: efficacy, cost-effectiveness, and antimicrobial resistance. *American Journal of Infection Control*. 32(8): 445-50. 2004.
208. Elhendy A, O'Leary EL, Xie F, McGrain AC, **Anderson JR**, Porter TR. Comparative accuracy of real-time myocardial contrast perfusion imaging and wall motion analysis during Dobutamine stress echocardiography. *Journal of the American College of Cardiology*. 44(11): 2185-91. 2004.
209. Chiu BC, Kolar C, Gapstur SM, Lawson T, **Anderson JR**, Weisenburger DD. Association of NAT and GST polymorphisms with non-Hodgkin's lymphoma: a population-based case-control study. *British Journal of Haematology*. 128(5): 610-5. 2005.
210. Donaldson SS, **Anderson JR**. Rhabdomyosarcoma: many similarities, a few philosophical differences. *Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology*. 23(12): 2586-7. 2005.
211. Enose Y, Destache CJ, Mack AL, **Anderson JR**, Ullrich F, Ciborowski PS, Gendelman HE. Proteomic fingerprints distinguish microglia, bone marrow, and spleen macrophage populations. *Glia*. 51(3): 161-72. 2005.
212. **Anderson JR**. More on data monitoring and large apparent treatment effects. *Contemporary Clinical Trials*. 26(3): 416-7. 2005.
213. Chiu BC, **Anderson JR**, Corbin D. Predictors of prostate cancer screening among health fair participants. *Public Health*. 119(8):686-93. 2005.
214. Tsutsui JM, Xie F, O'Leary EL, Elhendy A, **Anderson JR**, McGrain AC, Porter TR. Diagnostic accuracy and prognostic value of dobutamine stress myocardial contrast echocardiography in patients with suspected acute myocardial infarction. *Echocardiography (Mount Kisco, N.Y.)*. 22(6): 487-95. 2005.
215. Tsutsui JM, Elhendy A, **Anderson JR**, Xie F, McGrain AC, Porter TR. Prognostic value of dobutamine stress myocardial contrast perfusion echocardiography. *Circulation*. 112(10): 1444-50. 2005.
216. Bucklin BA, Hawkins JL, **Anderson JR**, Ullrich FA. Obstetric anesthesia workforce survey: twenty-year update. *Anesthesiology*. 103(3): 645-53. 2005.
217. **Anderson JR**, Neuberg DS. Analysis of outcome by response flawed. *Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology*. 23(31): 8122-3; au. 2005.
218. **Anderson JR**, Schonfeld TL. Patient consent in the era of de-identified research databases. *Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology*. 24(4): 720-1. 2006.
219. Lager JJ, Lyden ER, **Anderson JR**, Pappo AS, Meyer WH, Breitbart PP. Pooled analysis of phase II window studies in children with contemporary high-risk metastatic rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group. *Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology*. 24(21): 3415-22. 2006.
220. Meza JL, **Anderson J**, Pappo AS, Meyer WH, Meyer WH. Analysis of prognostic factors in patients with nonmetastatic rhabdomyosarcoma treated on intergroup rhabdomyosarcoma studies III and IV: the Children's Oncology Group. *Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology*. 24(24): 3844-51. 2006.

221. Raney B, **Anderson J**, Jenney M, Arndt C, Brecht I, Carli M, Bisogno G, Oberlin O, Rey A, Treuner J, Ullrich F, Stevens M, Stevens M, Stevens M, Stevens M, Stevens M. Late effects in 164 patients with rhabdomyosarcoma of the bladder/prostate region: a report from the international workshop. *The Journal of Urology*. 176(5): 2190-4; di. 2006.
222. Shonka NA, **Anderson JR**, Panwalkar AW, Reed EC, Steen PD, Ganti AK. Effect of diabetes mellitus on the epidemiology and outcomes of colon cancer. *Medical Oncology (Northwood, London, England)*. 23(4): 515-9. 2006.
223. Chang MN, Devidas M, **Anderson J**. One- and two-stage designs for phase II window studies. *Statistics in Medicine*. 26(13):2604-14. 2007.
224. Muelleman RL, Wadman MC, Tran TP, Ullrich F, **Anderson JR**. Rural motor vehicle crash risk of death is higher after controlling for injury severity. *The Journal of Trauma*. 62(1): 221-5; dis., 2007.
225. Heerema NA, Raimondi SC, **Anderson JR**, Biegel J, Camitta BM, Cooley LD, Gaynon PS, Hirsch B, Magenis RE, McGavran L, Patil S, Pettenati MJ, Pullen J, Rao K, Roulston D, Schneider NR, Shuster JJ, Sanger W, Sutcliffe MJ, van Tuinen P, Watson MS, Carroll AJ. Specific extra chromosomes occur in a modal number dependent pattern in pediatric acute lymphoblastic leukemia. *Genes, Chromosomes & Cancer*. 46(7): 684-93. 2007.
226. **Anderson JR**. Persistent coronary occlusion after myocardial infarction. *The New England Journal of Medicine*. 356(16): 1681; auth. 2007.
227. Rupp ME, Sholtz LA, Jourdan DR, Marion ND, Tyner LK, Fey PD, Iwen PC, **Anderson JR**. Outbreak of bloodstream infection temporally associated with the use of an intravascular needleless valve. *Clinical Infectious Diseases: an official publication of the Infectious Diseases Society of America*. 44(11): 1408-14. 2007.
228. Lovvorn HN, Westrup J, Opperman S, Boyle S, Shi G, **Anderson J**, Perlman EJ, Perantoni AO, Wills M, de Caestecker M. CITED1 expression in Wilms tumor and embryonic kidney. *Neoplasia (New York, N.Y.)*. 9(7): 589-600. 2007.
229. Burke M, **Anderson JR**, Kao SC, Rodeberg D, Qualman SJ, Wolden SL, Meyer WH, Breitfeld PP, Breitfeld PP. Assessment of response to induction therapy and its influence on 5-year failure-free survival in group III rhabdomyosarcoma: the Intergroup Rhabdomyosarcoma Study-IV experience--a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group. *Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology*. 25(31): 4909-13. 2007.
230. Arndt CA, Hawkins DS, Meyer WH, Sencer SF, Neglia JP, **Anderson JR**. Comparison of results of a pilot study of alternating vincristine/doxorubicin/cyclophosphamide and etoposide/ifosfamide with IRS-IV in intermediate risk rhabdomyosarcoma: a report from the Children's Oncology Group. *Pediatric Blood & Cancer*. 50(1): 33-6. 2008.
231. van den Heuvel-Eibrink MM, Grundy P, Graf N, Pritchard-Jones K, Bergeron C, Patte C, van Tinteren H, Rey A, Langford C, **Anderson JR**, de Kraker J. Characteristics and survival of 750 children diagnosed with a renal tumor in the first seven months of life: A collaborative study by the SIOP/GPOH/SFOP, NWTSG, and UKCCSG Wilms tumor study groups. *Pediatric Blood & Cancer*. 50(6): 1130-4. 2008.
232. Rupp ME, Fitzgerald T, Puumala S, **Anderson JR**, Craig R, Iwen PC, Jourdan D, Keuchel J, Marion N, Peterson D, Sholtz L, Smith V. Prospective, controlled, cross-over trial of alcohol-based hand gel in critical care units. *Infection Control and Hospital Epidemiology*. 29(1): 8-15.2008.

233. Rupp ME, Iwen PC, Tyner LK, Marion N, Reed E, **Anderson JR**. Routine sampling of air for fungi does not predict risk of invasive aspergillosis in immunocompromised patients. *The Journal of Hospital Infection*. 68(3): 270-1. 2008.
234. Raney B, **Anderson J**, Breneman J, Donaldson SS, Huh W, Maurer H, Michalski J, Qualman S, Ullrich F, Wharam M, Meyer W, Meyer W. Results in patients with cranial parameningeal sarcoma and metastases (Stage 4) treated on Intergroup Rhabdomyosarcoma Study Group (IRSG) Protocols II-IV, 1978-1997: report from the Children's Oncology Group. *Pediatric Blood & Cancer*. 51(1): 17-22. 2008.
235. Feresu SA, Zhang W, Puumala SE, Ullrich F, **Anderson JR**. The frequency and distribution of cardiovascular disease risk factors among Nebraska women enrolled in the WISEWOMAN screening p. *Journal of Women's Health* (2002). 17(4) 607-17. 2008.
236. Oberlin O, Rey A, Lyden E, Bisogno G, Stevens MC, Meyer WH, Carli M, **Anderson JR**. Prognostic factors in metastatic rhabdomyosarcomas: results of a pooled analysis from United States and European cooperative groups. *Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology*. 26(14): 2384-9. 2008.
237. Hayes-Jordan A, Stoner JA, **Anderson JR**, Rodeberg D, Weiner G, Meyer WH, Hawkins DS, Arndt CA, Paidas C, Paidas C. The impact of surgical excision in chest wall rhabdomyosarcoma: a report from the Children's Oncology Group. *Journal of Pediatric Surgery*. 43(5): 831-6. 2008.
238. Raney B, **Anderson J**, Arndt C, Crist W, Maurer H, Qualman S, Wharam M, Wiener E, Meyer W, Meyer W. Primary renal sarcomas in the Intergroup Rhabdomyosarcoma Study Group (IRSG) experience, 1972-2005: A report from the Children's Oncology Group. *Pediatric Blood & Cancer*. 51(3): 339-43. 2008.
239. Feresu SA, Zhang W, Puumala SE, Ullrich F, **Anderson JR**. Breast and cervical cancer screening among low-income women in Nebraska: findings from the Every Woman Matters program, 1993-2004. *Journal of Health Care for the Poor and Underserved*. 19(3): 797-813. 2008.
240. **Anderson JR**, Cain KC, Gelber RD. Analysis of survival by tumor response and other comparisons of time-to-event by outcome variables. *Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology*. 26(24): 3913-5. 2008.
241. O'Leary M, Krailo M, **Anderson JR**, Reaman GH. Progress in Childhood Cancer: 50 Years of Research Collaboration, a report from the Children's Oncology Group. *Seminars in Oncology*. 35(5): 484-93. 2008.
242. **Anderson JR**, Krailo MD. Problems Identified With Phase II Stopping Rules That Employ Response and Early-Progression Rates. *Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology*. 2009 Feb 1; 27(4):646-7; author reply 647. Epub 2008 Dec 22.
243. Fernandez CV, **Anderson J**, Breslow NE, Dome JS, Grundy PE, Perlman EJ, Green DM, Green DM. Anthropomorphic measurements and event-free survival in patients with favorable histology Wilms tumor: a report from the Children's Oncology Group. *Pediatric Blood & Cancer*. 52(2): 254-8. 2009.
244. **Anderson JR**, Schonfeld T. Research, not quality assurance. *Anesthesia and analgesia*. 108(1): 376; autho. 2009.
245. **Anderson JR**, Schonfeld TL. Data-sharing dilemmas: allowing pharmaceutical company access to research data. *IRB*. 31(3):17-9. 2009.

246. Ehrlich PF, Ferrer FA, Ritchey ML, **Anderson JR**, Green DM, Grundy PE, Dome JS, Kalapurakal JA, Perlman EJ, Shamberger RC. Hepatic Metastasis at Diagnosis in Patients with Wilms Tumor is not an Independent Adverse Prognostic Factor for Stage IV Wilms Tumor: A Report from the Children's Oncology Group/National Wilms Tumor Study Group. *Annals of Surgery*. Oct; 250(4):642-8. 2009.
247. Arndt CA, Stoner JA, Hawkins DS, Rodeberg DA, Hayes-Jordan AA, Paidas CN, Parham DM, Teot LA, Wharam MD, Breneman JC, Donaldson SS, **Anderson JR**, Meyer WH. Vincristine, actinomycin, and cyclophosphamide compared with vincristine, actinomycin, and cyclophosphamide alternating with vincristine, topotecan, and cyclophosphamide for intermediate-risk rhabdomyosarcoma: childrens oncology group study D9803. *Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology*. 27(31): 5182-8. 2009.
248. Davicioni E, **Anderson JR**, Buckley JD, Meyer WH, Triche TJ. Gene Expression Profiling for Survival Prediction in Pediatric Rhabdomyosarcomas: A Report from the Children's Oncology Group. *Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology*. Mar 1;28(7):1240-6. 2010.
249. Shamberger RC, **Anderson JR**, Breslow NE, Perlman EJ, Beckwith JB, Ritchey ML, Haase GM, Donaldson M, Grundy PE, Weetman R, Coppes MJ, Malogolowkin M, Shearer PD, Kletzel M, Thomas PR, Macklis R, Huff V, Weeks DA, Green DM. Long-term Outcomes for Infants With Very Low Risk Wilms Tumor Treated With Surgery Alone in National Wilms Tumor Study-5. *Annals of Surgery*. Mar; 251(3):555-8. 2010.
250. Huh WW, **Anderson JR**, Rodeberg D, Teot L, Yock T, Raney RB. Orbital sarcoma with metastases at diagnosis: a report from the Soft Tissue Sarcoma Committee of the Childrens Oncology Group. *Pediatric Blood & Cancer*. 54(7): 1045-7. 2010.
251. Devidas M, London WB, **Anderson JR**. The use of central laboratories and remote electronic data capture to risk-adjust therapy for pediatric acute lymphoblastic leukemia and neuroblastoma. *Seminars in Oncology*. 37(1): 53-9. 2010.
252. Kalapurakal JA, Green DM, Haase G, **Anderson JR**, Dome JS, Grundy PE. Outcomes of children with favorable histology Wilms tumor and peritoneal implants treated in National Wilms Tumor Studies-4 and -5. *International Journal of Radiation Oncology, Biology, Physics*. 77(2):554-8. 2010.
253. Wiederin JL, Donahoe RM, **Anderson JR**, Yu F, Fox H, Gendelman HE, Ciborowski P. Plasma Proteomic Analysis of Simian Immunodeficiency Virus Infection of Rhesus Macaques. *Journal of Proteome Research*. Sep 3; 9(9):4721-31. 2010.
254. **Anderson JR**, Barr FG, Hawkins DS, Parham DM, Skapek SX, Triche TJ. Fusion-Negative Alveolar Rhabdomyosarcoma: Modification of Risk Stratification Is Premature. *Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology*. Oct 10; 28(29):e587-8. 2010.
255. Minn AY, Lyden ER, **Anderson JR**, Million L, Arndt CA, Brown K, Hawkins DS, Donaldson SS. Early Treatment Failure in Intermediate-Risk Rhabdomyosarcoma: Results from IRS-IV and D9803--A Report from the Children's Oncology Group. *Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology*. Sep 20; 28(27):4228-32. 2010.

256. Raney RB, **Anderson JR**, Brown KL, Huh WW, Maurer HM, Meyer WH, Parham DM, Rodeberg DA, Wolden SL, Donaldson SS, Donaldson SS. Treatment results for patients with localized, completely resected (Group I) alveolar rhabdomyosarcoma on Intergroup Rhabdomyosarcoma Study Group (IRSG) protocols III and IV, 1984-1997: a report from the Children's Oncology Group. *Pediatric Blood & Cancer*. 55(4): 612-6. 2010.
257. Mascarenhas L, Lyden ER, Breitfeld PP, Walterhouse DO, Donaldson SS, Paidas CN, Parham DM, **Anderson JR**, Meyer WH, Hawkins DS. Randomized phase II window trial of two schedules of irinotecan with vincristine in patients with first relapse or progression of rhabdomyosarcoma: a report from the Children's Oncology Group. *Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology*. 28(30): 4658-63. 2010.
258. Raney B, Stoner J, **Anderson J**, Andrassy R, Arndt C, Brown K, Crist W, Maurer H, Qualman S, Wharam M, Wiener E, Meyer W, Hayes-Jordan A; Soft-Tissue Sarcoma Committee of the Children's Oncology Group. Impact of tumor viability at second-look procedures performed before completing treatment on the Intergroup Rhabdomyosarcoma Study Group protocol IRS-IV, 1991-1997: a report from the children's oncology group. *J Pediatr Surg*. 2010 Nov;45(11):2160-8.
259. Million L, **Anderson J**, Breneman J, Hawkins DS, Laurie F, Michalski J, Rodeberg D, Wharam M, Wolden S, Donaldson SS. Influence of Noncompliance with Radiation Therapy Protocol Guidelines and Operative Bed Recurrences for Children with Rhabdomyosarcoma and Microscopic Residual Disease: A Report from the Children's Oncology Group. *International Journal of Radiation Oncology, Biology, Physics*. Jun 1; 80(2):333-8. 2011.
260. La TH, Wolden SL, Rodeberg DA, Hawkins DS, Brown KL, **Anderson JR**, Donaldson SS. Regional Nodal Involvement and Patterns of Spread Along In-transit Pathways in Children With Rhabdomyosarcoma of the Extremity: A Report From the Children's Oncology Group. *International Journal of Radiation Oncology, Biology, Physics*. Jul 15; 80(4):1151-7. 2011.
261. Rodeberg DA, **Anderson JR**, Arndt CA, Ferrer FA, Raney RB, Jenney ME, Brecht IB, Koscielniak E, Carli M, Bisogno G, Oberlin O, Rey A, Ullrich F, Stevens MC, Meyer WH. Comparison of outcomes based on treatment algorithms for rhabdomyosarcoma (RMS) of the bladder/Prostate (BP): combined results from the children's oncology group (COG), german cooperative soft tissue sarcoma study (CWS), italian cooperative group (ICG), an. *International Journal of Cancer. Journal international du cancer*. Mar 1; 128(5):1232-9. 2011.
262. Perlman EJ, Grundy PE, **Anderson JR**, Jennings LJ, Green DM, Dome JS, Shamberger RC, Ruteshouser EC, Huff V. WT1 mutation and 11P15 loss of heterozygosity predict relapse in very low-risk wilms tumors treated with surgery alone: a Children's Oncology Group study. *Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology*. 29(6):698-703. 2011.
263. Malempati S, Rodeberg DA, Donaldson SS, Lyden ER, **Anderson JR**, Hawkins DS, Arndt CA. Rhabdomyosarcoma in infants younger than 1 year: a report from the Children's Oncology Group. *Cancer*. 117(15): 3493-501. 2011.
264. Beverly Raney R, Walterhouse DO, Meza JL, Andrassy RJ, Breneman JC, Crist WM, Maurer HM, Meyer WH, Parham DM, **Anderson JR**. Results of the Intergroup Rhabdomyosarcoma Study Group D9602 protocol, using vincristine and dactinomycin with or without cyclophosphamide and radiation therapy, for newly diagnosed patients with low-risk embryonal rhabdomyosarcoma: a report from the Soft. *Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology*. 29(10): 1312-8. 2011.

265. Hamilton TE, Ritchey ML, Haase GM, Argani P, Peterson SM, **Anderson JR**, Green DM, Shamberger RC. The management of synchronous bilateral Wilms tumor: a report from the National Wilms Tumor Study Group. *Annals of Surgery*. 253(5): 1004-10. 2011.
266. **Anderson JR**, Krailo M. The Childrens Oncology Group routinely applies "lack of efficacy" interim monitoring to its randomized clinical trials. *The American Journal of Bioethics*. 11(3): 18-9. 2011.
267. **Anderson JR**, High R. Alternatives to the standard Fleming, Harrington, and OBrien futility boundary. *Clinical Trials (London, England)*. 8(3): 270-6. 2011.
268. Schonfeld T, **Anderson J**. Dropout by design: advance planning for research participant noncompliance. *The American Journal of Bioethics*. 11(4): 18-20. 2011.
269. Tiwari MM, Hermsen ED, Charlton ME, **Anderson JR**, Rupp ME. Inappropriate intravascular device use: a prospective study. *The Journal of Hospital Infection*. 78(2): 128-32. 2011.
270. Pressey JG, **Anderson JR**, Crossman DK, Lynch JC, Barr FG. Hedgehog pathway activity in pediatric embryonal rhabdomyosarcoma and undifferentiated sarcoma: A report from the Childrens Oncology Group. *Pediatric blood & cancer*. 57(6): 930-8. 2011.
271. Williams RD, Al-Saadi R, Natrajan R, Mackay A, Chagtai T, Little S, Hing SN, Fenwick K, Ashworth A, Grundy P, **Anderson JR**, Dome JS, Perlman EJ, Jones C, Pritchard-Jones K. Molecular profiling reveals frequent gain of MYCN and anaplasia-specific loss of 4q and 14q in Wilms tumor. *Genes, Chromosomes & Cancer*. 50(12): 982-95. 2011.
272. Tiwari MM, Charlton ME, **Anderson JR**, Hermsen ED, Rupp ME. Inappropriate use of urinary catheters: A prospective observational study. *American Journal of Infection Control*. Feb; 40(1):51-4. 2012.
273. Gupta AA, **Anderson JR**, Pappo AS, Spunt SL, Dasgupta R, Indelicato DJ, Hawkins DS. Patterns of chemotherapy-induced toxicities in younger children and adolescents with rhabdomyosarcoma: A Report from the Children's Oncology Group Soft Tissue Sarcoma Committee. *Cancer*. Feb 15; 118(4):1130-7. 2012.
274. Khanna G, Rosen N, **Anderson JR**, Ehrlich PF, Dome JS, Gow KW, Perlman E, Barnhart D, Karolczuk K, Grundy P. Evaluation of diagnostic performance of CT for detection of tumor thrombus in children with Wilms tumor: A report from the Children's Oncology Group. *Pediatric Blood & Cancer*. Apr; 58(4):551-5. 2012.
275. Lin C, Donaldson SS, Meza JL, **Anderson JR**, Lyden ER, Brown CK, Morano K, Laurie F, Arndt CA, Enke CA, Breneman JC. Effect of Radiotherapy Techniques (IMRT vs. 3D-CRT) on Outcome in Patients With Intermediate-Risk Rhabdomyosarcoma Enrolled in COG D9803-A Report From the Childrens Oncology Group. *International Journal of Radiation Oncology, Biology, Physics*. Apr 1; 82(5):1764-70. 2012.
276. Kieran K, **Anderson JR**, Dome JS, Ehrlich PF, Ritchey ML, Shamberger RC, Perlman EJ, Green DM, Davidoff AM. Lymph node involvement in Wilms tumor: results from National Wilms Tumor Studies 4 and 5. *J Pediatr Surg*. 2012 Apr;47(4):700-6.
277. Rupp ME, Yu S, Huerta T, Cavalieri RJ, Alter R, Fey PD, Van Schooneveld T, **Anderson JR**. Adequate disinfection of a split-septum needleless intravascular connector with a 5-second alcohol scrub. *Infect Control Hosp Epidemiol*. Jul; 33(7):661-5.
278. Murphy AJ, Pierce J, de Caestecker C, Taylor C, **Anderson JR**, Perantoni AO, de Caestecker MP, Lovvorn HN 3rd. SIX2 and CITED1, markers of nephronic progenitor self-renewal, remain active in primitive elements of Wilms' tumor. *J Pediatr Surg*. 2012 Jun;47(6):1239-49.



279. Grundy PE, Green DM, Dirks AC, Berendt AE, Breslow NE, **Anderson JR**, Dome JS. Clinical significance of pulmonary nodules detected by CT and Not CXR in patients treated for favorable histology Wilms tumor on national Wilms tumor studies-4 and -5: a report from the Children's Oncology Group. *Pediatr Blood Cancer*. 2012 Oct;59(4):631-5.
280. Rupp ME, Cavalieri RJ, Lyden E, Kucera J, Martin M, Fitzgerald T, Tyner K, **Anderson JR**, VanSchooneveld TC. Effect of hospital-wide chlorhexidine patient bathing on healthcare-associated infections. *Infect Control Hosp Epidemiol*. 2012 Nov;33(11):1094-100.
281. Raney B, Huh W, Hawkins D, Hayes-Jordan A, Million L, Rodeberg D, Teot L, **Anderson J**; Soft Tissue Sarcoma Committee of the Children's Oncology Group, Arcadia, CA. Outcome of patients with localized orbital sarcoma who relapsed following treatment on Intergroup rhabdomyosarcoma Study Group (IRSG) Protocols-III and -IV, 1984-1997: a report from the Children's Oncology Group. *Pediatr Blood Cancer*. 2013 Mar;60(3):371-6.
282. Ehrlich PF, **Anderson JR**, Ritchey ML, Dome JS, Green DM, Grundy PE, Perlman EJ, Kalapurakal JA, Breslow NE, Shamberger RC. Clinicopathologic Findings Predictive of Relapse in Children With Stage III Favorable-Histology Wilms Tumor. *J Clin Oncol*. 2013 Mar 20;31(9):1196-201.
283. Goldman S, Smith L, **Anderson JR**, Perkins S, Harrison L, Geyer MB, Gross TG, Weinstein H, Bergeron S, Shiramizu B, Sanger W, Barth M, Zhi J, Cairo MS. Rituximab and FAB/LMB 96 chemotherapy in children with Stage III/IV B-cell non-Hodgkin lymphoma: a Children's Oncology Group report. *Leukemia*. 2013 Apr;27(5):1174-7.
284. Routh JC, Grundy PE, **Anderson JR**, Retik AB, Kurek KC. B7-H1 as a Biomarker for Therapy Failure in Patients with Favorable Histology Wilms Tumor. *J Urol*. 2013 Apr;189(4):1487-92.
285. Dome JS, Fernandez CV, Mullen EA, Kalapurakal JA, Geller JI, Huff V, Gratijs EJ, Dix DB, Ehrlich PF, Khanna G, Malogolowkin MH, **Anderson JR**, Naranjo A, Perlman EJ; on behalf of the COG Renal Tumors Committee. Children's Oncology Group's 2013 blueprint for research: Renal tumors. *Pediatr Blood Cancer*. 2013 Jun;60(6):994-1000.
286. Kieran K, **Anderson JR**, Dome JS, Ehrlich PF, Ritchey ML, Shamberger RC, Perlman EJ, Green DM, Davidoff AM. Is adrenalectomy necessary during unilateral nephrectomy for Wilms Tumor? A report from the Children's Oncology Group. *J Pediatr Surg*. 2013 Jul;48(7):1598-603.
287. Rudzinski ER, Teot LA, **Anderson JR**, Moore J, Bridge JA, Barr FG, Gastier-Foster JM, Skapek SX, Hawkins DS, Parham DM. Dense pattern of embryonal rhabdomyosarcoma, a lesion easily confused with alveolar rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group. *Am J Clin Pathol*. 2013 Jul;140(1):82-90.
288. Skapek SX, **Anderson J**, Barr FG, Bridge JA, Gastier-Foster JM, Parham DM, Rudzinski ER, Triche T, Hawkins DS. PAX-FOXO1 fusion status drives unfavorable outcome for children with rhabdomyosarcoma: a children's oncology group report. *Pediatr Blood Cancer*. 2013 Sep;60(9):1411-7
289. Skapek SX, **Anderson JR**, Hill DA, Henry D, Spunt SL, Meyer W, Kao S, Hoffer FA, Grier HE, Hawkins DS, Raney RB. Safety and efficacy of high-dose tamoxifen and sulindac for desmoid tumor in children: Results of a Children's Oncology Group (COG) Phase II Study. *Pediatr Blood Cancer*. 2013 Jul;60(7):1108-12.
290. Bryant KA, Roberts AL, Rupp ME, **Anderson JR**, Lyden ER, Fey PD, Van Schooneveld TC. Susceptibility of enterococci to daptomycin is dependent upon testing methodology. *Diagn Microbiol Infect Dis*. 2013 Aug;76(4):497-501.

291. Gratijs EJ, Jennings LJ, **Anderson JR**, Dome JS, Grundy P, Perlman EJ. Gain of 1q is associated with inferior event-free and overall survival in patients with favorable histology Wilms tumor: A report from the children's oncology group. *Cancer*. 2013 Nov 1;119(21):3887-94.
292. Weiss AR, Lyden ER, **Anderson JR**, Hawkins DS, Spunt SL, Walterhouse DO, Wolden SL, Parham DM, Rodeberg DA, Kao SC, Womer RB. Histologic and Clinical Characteristics Can Guide Staging Evaluations for Children and Adolescents With Rhabdomyosarcoma: A Report From the Children's Oncology Group Soft Tissue Sarcoma Committee. *J Clin Oncol*. 2013 Sep 10;31(26):3226-3232.
293. Wilson RA, Teng L, Bachmeyer KM, Bissonnette ML, Husain AN, Parham DM, Triche TJ, Wing MR, Gastier-Foster JM, Barr FG, Hawkins DS, **Anderson JR**, Skapek SX, Volchenbom SL. A Novel Algorithm for Simplification of Complex Gene Classifiers in Cancer. *Cancer Res*. 2013 Sep 15;73(18):5625-32.
294. Devidas M, **Anderson JR**. Considerations in the design of clinical trials for pediatric acute lymphoblastic leukemia. *Clin Investig (Lond)*. 2013 Sep;3(9). Doi:10.4155/cli.13.71. PubMed PMID: 24115727 PubMed Central PMCID: PMC3834963.
295. Jacob AD, O'Brien D, Singh RK, Comiskey DF Jr, Littleton RM, Mohammad F, Gladman JT, Widmann MC, Jeyaraj SC, Bolinger C, **Anderson JR**, Barkauskas DA, Boris-Lawrie K, Chandler DS. Stress-induced isoforms of MDM2 and MDM4 correlate with high-grade disease and an altered splicing network in pediatric rhabdomyosarcoma. *Neoplasia*. 2013 Sep;15(9):1049-63.
296. Spalding AC, Hawkins DS, Donaldson SS, **Anderson JR**, Lyden E, Laurie F, Wolden SL, Arnt CA, Michalski JM. The effect of radiation timing on patients with high-risk features of parameningeal rhabdomyosarcoma: an analysis of IRS-IV and D9803. *Int J Radiat Oncol Biol Phys*. 2013 Nov 1;87(3):512-6.
297. Rosenberg AR, **Anderson JR**, Lyden E, Rodeberg DA, Wolden SL, Kao SC, Parham DM, Arndt C, Hawkins DS. Early response as assessed by anatomic imaging does not predict failure-free survival among patients with Group III rhabdomyosarcoma: A report from the Children's Oncology Group. *Eur J Cancer*. 2013 Dec 18. Pii:s0959-8049(13)01027-7.
298. Shern JR, Chen L, Chmielecki J, Wei JS, Patidar R, Rosenberg M, Ambrogio L, Auclair D, Wang J, Song YK, Tolman C, Hurd L, Liao H, Zhang S, Bogen D, Brohl AS, Sindiri S, Catchpole D, Badgett T, Getz G, Mora J, **Anderson JR**, Skapek SX, Barr FG, Meyerson M, Hawkins DS, Khan J. Comprehensive Genomic Analysis of Rhabdomyosarcoma Reveals a Landscape of Alterations Affecting a Common Genetic Axis in Fusion-Positive and Fusion-Negative Tumors. *Cancer Discov*. 2014 Jan 16. [Epub ahead of print] PubMed PMID: 24436047.
299. Merks JH, De Salvo GL, Bergeron C, Bisogno G, De Paoli A, Ferrari A, Rey A, Oberlin O, Stevens MC, Kelsey A, Michalski J, Hawkins DS, **Anderson JR**. Parameningeal rhabdomyosarcoma in pediatric age: results of a pooled analysis from North America and European cooperative groups. *Ann Oncol*. 2014 Jan;25(1):231-6.
300. Murphy AJ, Pierce J, de Caestecker C, Libes J, Neblett D, de Caestecker M, Perantoni AO, Tanigawa S, **Anderson JR**, dome JS, Das A, Carroll TJ, Lovvorn HN 3rd. Aberrant activation, nuclear localization, and phosphorylation of yes-associated protein-1 in the embryonic kidney and Wilms tumor. *Pediatr Blood Cancer*. 2014 Feb;61(2):198-205.
301. Rudzinski ER, **Anderson JR**, Lyden ER, Bridge JA, Barr FG, Gastier-Foster JM, Bachmeyer K, Skapek SX, Hawkins DS, Teot LA, Parham DM. Myogenin, AP2 $\beta$ , NOS-1, and HMGA2 are surrogate markers of fusion status in rhabdomyosarcoma: a report from the soft tissue sarcoma committee of the children's oncology group. *Am J Surg Pathol*. 2014 May;38(5):654-9.

302. **Anderson JR**, Schonfeld TL. Informed consent for comparative effectiveness trials. (letter) *N Engl J Med*. 2014 May 15;370(20):1958.
303. Goldman S, Smith L, Galardy P, Perkins SL, Frazer JK, Sanger W, **Anderson JR**, Gross TG, Weinstein H, Harrison L, Shiramizu B, Barth M, Cairo MS. Rituximab with chemotherapy in children and adolescents with central nervous system and/or bone marrow-positive Burkitt lymphoma/leukaemia: a Children's Oncology Group Report. *Br J Haematol*. 2014 Nov;167(3):394-401.
304. Walterhouse DO, Pappo AS, Meza JL, Breneman JC, Hayes-Jordan AA, Parham DM, Cripe TP, **Anderson JR**, Meyer WH, Hawkins DS. Shorter-Duration Therapy Using Vincristine, Dactinomycin, and Lower-Dose Cyclophosphamide With or Without Radiotherapy for Patients With Newly Diagnosed Low-Risk Rhabdomyosarcoma: A report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group. *J Clin Oncol*. 2014 Nov 1;32(31):3547-52.
305. Maschietto M, Williams RD, Chagtai T, Popov SD, Sebire NJ, Vujanic G, Perlman E, **Anderson JR**, Grundy P, Dome JS, Pritchard-Jones K. TP53 mutational status is a potential marker for risk stratification in Wilms tumour with diffuse anaplasia. *PLoS One*. 2014 Oct 14;9(10):e109924.
306. McCarville MB, Muzzafar S, Kao SC, Coffin CM, Parham DM, **Anderson JR**, Spunt SL. Imaging Features of Alveolar Soft-Part Sarcoma: A report from Children's Oncology Group Study ARST0332. *AJR Am J Roentgenol*. 2014 Dec;203(6):1345-52.
307. Rudzinski ER, **Anderson JR**, Hawkins DS, Skapek SX, Parham DM, Teot LA. The World Health Organization Classification of Skeletal Muscle Tumors in Pediatric Rhabdomyosarcoma: A report from the Children's Oncology Group. *Arch Pathol Lab Med*. 2015 May 19. [Epub ahead of print] PubMed PMID: 25989287.
308. Shiramizu B, Goldman S, Smith L, Agsalda-Garcia M, Galardy P, Perkins SL, Frazer JK, Sanger W, **Anderson JR**, Gross TG, Weinstein H, Harrison L, Barth MJ, Mussolin L, Cairo MS. Impact of Persistent Minimal Residual Disease Post-Consolidation Therapy in Children and Adolescents With Advanced Burkitt Leukaemia: A Children's Oncology Group Pilot Study Report. *Br J Haematol*. 2015 Aug; 170(3):367-371.
309. Hingorani P, Missiaglia E, Shipley J, **Anderson JR**, Triche TJ, Delorenzi M, Gastier-Foster J, Wing M, Hawkins DS, Skapek SX. Clinical Application of Prognostic Gene Expression Signature in Fusion Gene-Negative Rhabdomyosarcoma: A report from the Children's Oncology Group. *Clin Cancer Res*. 2015 Oct 15; 21(20):4733-4739.
310. Rudzinski ER, **Anderson JR**, Hawkins DS, Skapek SX, Parham DM, Teot LA. The World Health Organization Classification of Skeletal Muscle Tumors in Pediatric Rhabdomyosarcoma: A Report From the Children's Oncology Group. *Arch Pathol Lab Med*. 2015 Oct; 139(10):1281-1287.
311. Wolden SL, Lyden ER, Arndt CA, Hawkins DS, **Anderson JR**, Rodeberg DA, Morris CD, Donaldson SS. Local Control for Intermediate-Risk Rhabdomyosarcoma: Results From D9803 According to Histology, Group, Site, and Size: A report from the Children's Oncology Group. *Int J Radiat Oncol Biol Phys*. 2015 Dec 1; 93(5):1071-1076.
312. Oberlin O, Rey A, Brown KL, Bisogno G, Koscielniak E, Stevens MC, Hawkins DS, Meyer WH, La TH, Carli M, **Anderson JR**. Prognostic Factors for Outcome in Localized Extremity Rhabdomyosarcoma. Pooled Analysis from Four International Cooperative Groups. *Pediatr Blood Cancer*. 2015 Dec; 62(12):2125-2131.

313. Weigel BJ, Lyden E, **Anderson JR**, Meyer WH, Parham DM, Rodeberg DA, Michalski JM, Hawkins DS, Arndt CA. Intensive Multiagent Therapy, Including Dose-Compressed Cycles of Ifosfamide/Etoposide and Vincristine/Doxorubicin/Cyclophosphamide, Irinotecan, and Radiation, in Patients With High-Risk Rhabdomyosarcoma: A report from the Children's Oncology Group. *J Clin Oncol*. 2016 Jan 10; 34(2):117-122.
314. Fernandez CV, Perlman EJ, Mullen EA, Chi YY, Hamilton TE, Gow KW, Ferrer FA, Barnhart DC, Ehrlich PF, Khanna G, Kalapurakal JA, Bocking T, Huff V, Tian J, Geller JI, Grundy PE, **Anderson JR**, Dome JS, Shamberger RC. Clinical Outcome and Biological Predictors of Relapse After Nephrectomy Only for Very Low-risk Wilms Tumor: A report from Children's Oncology Group AREN0532. *Ann Surg*. 2017 Apr;265(4):835-840.
315. Wee AG, Zimmerman LM, **Anderson JR**, Nunn ME, Loberiza FR, Sitorius MA, Pullen CH. Promoting Oral Cancer Examinations to Medical Primary Care Providers: A Cluster Randomized Trial. *J Public Health Dent* 2016 September 76(4):340-349.
316. Arnold MA, **Anderson JR**, Gastier-Foster JM, BAR FG, Skapek SX, Hawkins DS, Raney RB Jr, Parham DM, Teot LA, Rudzinski ER, Walterhouse DO. Histology, Fusion Status, and Outcome in Alveolar Rhabdomyosarcoma With Low-risk Clinical Features: A report from the Children's Oncology Group. *Pediatr Blood Cancer*, 2016 April 63(4):634-639.
317. Fresneau B, Hackshaw A, Hawkins DS, Paulussen M, **Anderson JR**, Judson I, Litiere S, Dirksen U, Lewis I, van den Berg H, Gaspar N, Gelderblom H, Whelan J, Boddy AV, Wheatley K, Pignon JP, De Vathaire F, Le Deley MC, Le Teuff G. Investigation the Heterogeneity of Alkylating Agents' Efficacy and Toxicity Between Sexes: A Systematic Review and Meta-Analysis of Randomized Trials Comparing Cyclophosphamide and Ifosfamide (MAIAGE study). *Pediatr Blood Cancer*. 2017 Aug;64(8). [Epub 2017 Jan 23].
318. Walterhouse DO, Pappo AS, Meza JL, Breneman JC, Hayes-Jordan A, Parham DM, Cripe TP, **Anderson JR**, Meyer WH, Hawkins DS. Reduction of Cyclophosphamide Dose for Patients with Subset 2 Low-Risk Rhabdomyosarcoma is Associated with an Increased Risk of Recurrence: A report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group. *Cancer*. 2017 Jun 15;123(12):2368-2375.
319. Ermoian RP, Breneman J, Walterhouse DO, Chi YY, Meza J, **Anderson J**, Hawkins DS, Hayes-Jordan AA, Parham DM, Yock TI, Donaldson SS, Wolden SL. 45 Gy is Not Sufficient Radiotherapy Dose for Group III Orbital Embryonal Rhabdomyosarcoma After Less than Complete Response to 12 Weeks of ARST0331 Chemotherapy: A report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group. *Pediatr Blood Cancer*. 2017 Sep; 64(9).
320. Fernandez CV, Mullen EA, Chi YY, Ehrlich PF, Perlman EJ, Kalapurakal JA, Khanna G, Paulino AC, Hamilton TE, Gow KW, Tochner Z, Hoffe FA, Withycombe JS, Shamberger RC, Kim Y, Geller JI, **Anderson JR**, Grundy PE, Dome JS. Outcome and Prognostic Factors in Stage III Favorable-Histology Wilms Tumor: A report from the Children's Oncology Group Study AREN0532. *J Clin Oncol* . 2018 Jan 20;36(3):254-261.
321. Rudzinski ER, **Anderson JR**, Chi YY, Gastier-Foster JM, Astbury C, Barr FG, Skapek SX, Hawkins DS, Weigel BJ, Pappo A, Meyer WH, Arnold MA, Teot LA, Parham DM. Histology, Fusion Status, and Outcome in Metastatic Rhabdomyosarcoma: A report from the Children's Oncology Group. *Pediatr Blood Cancer*. 2017 Dec; 64(12). [Epub 2017 May 18] PubMed Central PMCID: PMC5647228.

322. Dix DB, Seibel NL, Chi YY, Khanna G, Gratiias E, **Anderson Jr**, Mullen EA, Geller JI, Kalapurakal JA, Paulino AC, Perlman EJ, Ehrlich PF, Malogolowkin M, Gastier-Foster JM, Wagner E, Grundy PE, Fernandez CV, Dome JS. Treatment of Stage IV Favorable Histology Wilms Tumor With Lung Metastases: A Report from the Children's Oncology Group AREN0533 Study. *J Clin Oncol*. 2018 Jun 1; 36(16):1564-1570.
323. Gupta AA, Chi YY, **Anderson JR**, Lyden E, Weigel B, Arndt C, Meyer WH, Rosenberg A, Hawkins DS. Patterns of Chemotherapy-induced Toxicities and Outcome in Children and Adolescents with Metastatic Rhabdomyosarcoma: A report from the Children's Oncology Group. *Pediatr Blood Cancer*. 2017 Sep;64(9). [Epub 2017 Mar 23].
324. Gupta AA, Chi YY, **Anderson JR**, Lyden E, Weigel B, Arndt C, Meyer WH, Rosenberg A, Hawkins DS. Patterns of Chemotherapy-Induced Toxicities and Outcome in Children and Adolescents with Metastatic Rhabdomyosarcoma: A report from the Children's Oncology Group. *Pediatr Blood Cancer*. 2017 Sep; 64(9) [Epub 2017 Mar 23] PubMed PMID: 28333415. PubMed Central PMCID: PMC5567865.
325. Fresneau B, Hackshaw A, Hawkins DS, Paulussen M, **Anderson JR**, Judson I, Litiere S, Dirksen U, Lewis I, van den Berg H, Gaspar N, Gelderblom H, Whelan J, Boddy AV, Wheatley K, Pignon JP, De Vathaire F, Le Deley MC, Le Teuff G. Investigating the Heterogeneity of Alkylating Agents' Efficacy and Toxicity Between Sexes: A Systematic Review and Meta-analysis of Randomized Trials Comparing Cyclophosphamide and Ifosfamide. *Pediatr Blood Cancer*. 2017 Aug; 64 (8). [Epub 2017 Jan 23]. PubMed PMID: 28111876.
326. Walterhouse DO, Pappo AS, Meza JL, Breneman JC, Hayes-Jordan A, Parham DM, Cripe TP, **Anderson JR**, Meyer WH, Hawkins DS. Reduction of Cyclophosphamide Dose for Patients With Subset 2 Low-Risk Rhabdomyosarcoma is Associated With an Increased Risk of Recurrences: A report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group. *Cancer*. 2017 Jun 15; 123(12):2368-2375. [Epub 2017 Feb 17]. PubMed PMID: 28211936; PubMed Central PMCID: PMC5662934.
327. Fernandez CV, Perlman EJ, Mullen EA, Chi YY, Hamilton TE, Gow KW, Ferrer FA, Barnhart DC, Ehrlich PF, Khanna G, Kalapurakal JA, Bocking T, Huff V, Tian J, Geller JI, Grundy PE, **Anderson JR**, Dome JS, Shamberger RC. Clinical Outcome and Biological Predictors of Relapse after Nephrectomy Only for Very Low-risk Wilms Tumor: A report from Children's Oncology Group AREN0532. *Ann Surg* 2017 Apr; 265(4):834-840. PubMed PMID: 27811504; PubMed Central PMCID: PMC5145762.
328. Fernandez CV, Mullen EA, Chi YY, Ehrlich PF, Perlman EJ, Kalapurakal JA, Khanna G, Paulino AC, Hamilton TE, Gow KW, Tochner Z, Hoffer FA, Withycombe JS, Shamberger RC, Kim Y, Geller JI, **Anderson JR**, Grundy PE, Dome JS. Outcome and Prognostic Factors in Stage III Favorable-Histology Wilms Tumor: A Report From the Children's Oncology Group Study AREN0532. *J Clin Oncol*. 2018 Jan 20; 36(3):354-361.
329. Dix DB, Seibel NL, Chi YY, Khanna G, Gratiias E, **Anderson JR**, Mullen EA, Geller JI, Kalapurakal JA, Paulino AC, Perlman EJ, Ehrlich PF, Malogolowkin M, Gastier-Foster JM, Wagner E, Grundy PE, Fernandez CV, Dome JS. Treatment of Stage IV Favorable Histology Wilms Tumor With Lung Metastases: A Report From the Children's Oncology Group AREN0533 Study. *J Clin Oncol*. 2018 Jun 1; 36(16):1564-1570.

330. Robert C, Ribas A, Hamid O, Daud A, Wolchok JD, Joshua AM, Hwu WJ, Weber JS, Gangadhar TC, Joseph RW, Dronca R, Patnaik A, Zarour H, Kefford R, Hersey P, Zhang J, **Anderson J**, Diede SJ, Ebbinghaus S, Hodi FS. Durable Complete Responses After Discontinuation of Pembrolizumab in Patients With Metastatic Melanoma. *J Clin Oncol*. 2018 Jun 10; 36(17):1688-1674.
331. Fernandez CV, MullenEA, Chi YY, Ehrlich PF, Perlman EJ, Kalapurakal JA, Khanna G, Paulino AC, Hamilton TE, Gow KW, Tochner Z, Hoffer FA, Withycombe JS, Shamberger RC, Kim Y, Geller JI, **Anderson, JR**, Grundy PE, Dome JS. *J Clin Oncol*. 2018 Jan 20; 36(3): 254-261.
332. Hawkins DS, Chi YY, **Anderson JR**, Tian J, Arndt CAS, Bomgaars L, Donaldson SS, Hayes-Jordan A, Mascarenhas L, McCarville MB, McCune JS, McCowage G, Million L, Morris CD, Parham DM, Rodeberg DA, Rudzinski ER, Shnorhavorian M, Spunt SL, Skapek SX, Teot LA, Wolden A, Yock TI, Meyer WH. Addition of Vincristine and Irinotecan to Vincristine, Dactinomycin, and Cyclophosphamide Does Not Improve Outcome for Intermediate-Risk Rhabdomyosarcoma: A Report From the Children's Oncology Group. *J Clin Oncol*. 2018 Sep 20; 36(27): 2770-2777.
333. Seibel NL, Chi YY, Perlman EJ, Tian J, Sun J, **Anderson JR**, Ritchey ML, Thomas PR, Miser J, Kalapurakal JA, Grundy PE, Green DM. Impact of Cyclophosphamide and Etoposide in Outcome of Clear Cell Sarcoma of the Kidney Treated on the National Wilms Tumor Study-5 (NWT5-5). *Pediatr Blood Cancer*. 2018 Sep 25:e27450. PubMed PMID: 30255545.
334. Minard-Colin V, Walterhouse D, Bisogno G, Martelli H, **Anderson J**, Rodeberg DA, Ferrari A, Jenney M, Wolden S, De Salvo G, Arndt C, Merks JHM, Gallego S, Schwob D, Haie-Meder C, Bergeron C, Stevens MCG, Oberlin O, Hawkins D; International Society of Pediatric Oncology Sarcoma Committee, the Children's Oncology Group, the Italian Cooperative Soft Tissue Sarcoma Group, and the European Pediatric Soft Tissue Sarcoma Study Group. Localized vaginal/Uterine rhabdomyosarcoma-results of a pooled analysis from four international cooperative groups. *Pediatr Blood Cancer*. 2018 Sep; 65(9):e27096.
335. Mullen EA, Chi YY, Hibbitts E, **Anderson JR**, Steacy KJ, Geller JI, Green DM, Khanna G, Malogolowkin MH, Grundy PE, Fernandez CV, Dome JS. Impact of Surveillance Imaging Modality on Survival After Recurrence in Patients With Favorable-Histology Wilms Tumor: A Report From the Children's Oncology Group. *J Clin Oncol*. 2018 Oct 18, 36(34). PubMed PMID: 30335557.
336. Malempati S, Weigel BJ, Chi YY, Tian J, **Anderson JR**, Parham DM, Teot LA, Rodeberg DA, Yock TI, Shulkin BL, Spunt SL, Meyer WH, Hawkins DS. The Addition of Cixutumumab or Temozolomide to Intensive Multiagent Chemotherapy is Feasible But Does Not Improve Outcome for Patients with Metastatic Rhabdomyosarcoma: A Report from the Children's Oncology Group *Cancer*. 2019 Jan 15; 125(2):290-297.
337. Walterhouse DO, Barkauskas DA, Hall D, Ferrari A, De Salvo GL, Koscielniak E, Stevens MCG, Martelli H, Seitz G, Rodeberg DA, Shnorhavorian M, Dasgupta R, Breneman JC, **Anderson JR**, Bergeron C, Bisogno G, Meyer WH, Hawkins DS, Minard-Colin V. Demographic and Treatment Variables Influencing Outcome for Localized Paratesticular Rhabdomyosarcoma: Results from a Pooled Analysis of North American and European Cooperative Groups. *J Clin Oncol*. 2018 Oct 23; 36(35). PubMed PMID: 30351998.
338. Wang M, Chen C, Jemielita T, **Anderson, J**, Li XN, HuC, Kang SP, Ibrahim N, Ebbinghaus S. Are Tumor Size Changes Predictive of Survival for Checkpoint Blockade Based Immunotherapy in Metastatic Melanoma? *J Immunother Cancer* 2019 Feb 8; 7(1):39.

339. Frazer JK, Li KJ, Galardy PJ, Perkins SL, Auperin A, **Anderson JR**, Pinkerton R, Buxton A, Gross TG, Michon J, Leverger G, Weinstein HJ, Harrison L, Shiramizu B, Barth MJ, Goldman SC, Patte C, Cairo MS. Excellent Outcomes in Children and Adolescents with CNS(+) Burkitt Lymphoma or Other Mature B-NHL Using Only Intrathecal and Systemic Chemoimmunotherapy: Results from FAB/LMB96 and COG ANHLO1P1. *Br J Haematol.* 2019 Apr; 185(2): 374-377.
340. Mascarenhas L, Lyden ER, Breitfeld PP, Walterhouse DO, Donaldson SS, Rodeberg DA, Parham DM, **Anderson JR**, Meyer WH, Hawkins DS. Risk-based Treatment for Patients With First Relapse or Progression of Rhabdomyosarcoma. A report from the Children's Oncology Group. *Cancer* 2019 Aug 1; 125(15):2602-2609.
341. Long GV, Dummer R, Hamid O, Gajewski TF, Caglevic C, Dalle S, Arance A, Carlino MS, Grob JJ, Kim TM, Demidov L, Robert C, Larkin J, **Anderson JR**, Maleski J, Jones M, Diede SJ, Mitchel TC. Epcadostat Plus Pembrolizumab Versus Placebo Plus Pembrolizumab in Patients with Unresectable or Metastatic Melanoma (ECHO-301/KEYNOTE-252): A Phase 3, Randomized, Double-blind Study. *Lancet Oncol.* 2019 June 17. PubMed PMID: 31221619.
342. Dix DB, Fernandez CV, Chi YY, Mullen EA, Geller JI, Gratias EJ, Khanna G, Kalapurakal JA, Perlman EJ, Seibel NL, Ehrlich PF, Malogolowkin M, **Anderson J**, Gastier-Foster J, Shamberger RC, Kim Y, Grundy PE, Dome JS, AREN0532 and AREN0533 Study Committees. Augmentation of Therapy for Combined Loss of Heterozygosity 1p and 16q in Favorable Histology Wilms Tumor: A Children's Oncology Group AREN0532 and AREN0533 Study Report. *J Clin Oncol* 2019 Oct 20; 37(30):2769-2777.
343. Mascarenhas L, Chi YY, Hingorani P, **Anderson JR**, Lyden ER, Rodeberg DA, Indelicato DJ, Kao SC, Dasgupta R, Spunt SL, Meyer WH, Hawkins DS. Randomized Phase II Trial of Bevacizumab or Temozolomide in Combination With Chemotherapy for First Relapse Rhabdomyosarcoma: A Report from The Children's Oncology Group. *J Clin Oncol* 2019 Nov 1; 37(31):2866-2874.
344. Long GV, Dummer R, Hamid O, Gajewski TF, Caglevic C, Dalle S, Arance A, Carlino MS, Grob JJ, Kim TM, Demidov L, Robert C, Larkin J, **Anderson JR**, Maleski J, Jone M, Diede SJ, Mitchel TC. Epcadostat Plus Pembrolizumaab Versus Placebo Pembrolizumab in Patients With Unresectable or Metastatic Melanoma (ECHO-301/KEYNOTE-252): A Phase 3, Rancomized, Double-blind Study. *Lancet Oncol* 2019 Aug: 20(8):1083-1097.
345. Dix DB, Fernandez CV, Chi YY, Mullen EA, Geller JI, Gratias EJ, Khanna G, Kalapurakal JA, Perlman EJ, Seibel NL, Ehrlich PF, Malogolowkin M, **Anderson J**, Gastier-Foster J, Shamberger RC, Kim Y, Grundy PE, Dome JS; AREN0532 and AREN0533 study committees. Augmentation of Therapy for Combined Loss of Heterozygosity 1p and 16q in Favorable Histology Wilms Tumor: A Children's Oncology Group AREN0532 and AREN0533 Study Report. *J Clin Oncol* 2019 Oct 20; 37(30):2769-2777.
346. Mascarenhas L et al. Keynote-716: Phase III Study of Adjuvant Pembrolizumab Versus Placebo in Resected High-Risk Stage II Melanoma. *Oncology* 2019. PMID 31870188.
347. Spunt SL et al. A Risk-Based Treatment Strategy for Non-Rhabdomyosarcoma Soft-Tissue Sarcomas in Patients Younger Than 30 Years (ARSTO332): A Children's Oncology Group Prospective Study. *Lancet Oncol.* 2019. PMID 31786124.
348. Schmidt EV, Chisamore MJ, Chaney MF, Maradeo ME, **Anderson J**, Baltus BA, Pinheiro EM, Uebele VN. Assessment of Clinical Activity of PD-1 Checkpoint Inhibitor Combination Therapies Reported in Clinical Trials. *JAMA* 2020 Feb 12; 3(2):1-12.

349. Weiss AR, Chen YL, Scharschmidt TJ, Chi YY, Tian J, Black JO, Davis JL, Fanburg-Smith JC, Zambrano E, **Anderson J**, Arens R, Binitie O, Choy E, Davis JW, Hayes-Jordan A, Kao SC, Kayton ML, Kessel S, Lim R, Meyer WH, Million L, Okuno SH, Ostrenga A, Parisi MT, Pryma DA, Randall RL, Rosen MA, Schlapkohl M, Shulkin BL, Smith EA, Sorger JI, Terezakis S, Hawkins DS, Spunt SL, Wang D. Pathological Response in Children and Adults with Large Unresected Intermediate-grade or High-grade Soft Tissue Sarcoma Receiving Preoperative Chemoradiotherapy With or Without Pazopanib (ARST1321): A Multicentre, Randomised, Open-label, Phase 2 Trial. *Lancet Oncol.* 2020 Jul 20:S1470-2045(20)30325-9. doi:10.1016/S1470-2045.
350. Daw NC, Chi YY, Kalapurakal JA, Kim Y, Hoffer FA, Geller JI, Perlman EJ, Ehrlich PF, Mullen EA, Warwick AB, Grundy PE, Paulino AC, Gratias E, Ward D, **Anderson JR**, Khanna G, Tornwall B, Fernandez CV, Dome JS; AREN0321 Study Committee. Activity of Vincristine and Irinotecan in Diffuse Anaplastic Wilms Tumor and Therapy Outcomes of Stage II to IV Disease: Results of the Children's Oncology Group AREN0321 Study. *J Clin Oncol.* 2020 May 10;38(14):1558-1568.
351. Luke JJ, Ascierto PA, Carlino MS, Gershenwald JE, Grob JJ, Hauschild A, Kirkwood JM, Long GV, Mohr P, Robert C, Ross M, Scolyer RA, Yoon CH, Poklepovic A, Rutkowski P, **Anderson JR**, Ahsan S, Ibrahim N, M Eggermont AM. KEYNOTE-716:Phase III Study of Adjuvant Pembrolizumab versus Placebo in Resected High-risk Stage II Melanoma. *Future Oncol.* 2020 Jan;16(3):4429-4438.
352. Spunt SL, Million L, Chi YY, **Anderson J**, Tian J, Hibbitts E, Coffin C, McCarville MB, Randall RL, Parham DM, Black JO, Kao SC, Hayes-Jordan A, Wolden S, Laurie F, Speights R, Kawashima E, Skapek SX, Meyer W, Pappo AS, Hawkins DS. A Risk-based Treatment Strategy for Non-rhabdomyosarcoma Soft-tissue Sarcomas in Patients Younger than 30 years (ARST0332): A Children's Oncology Group Prospective Study. *Lancet Oncol.* 2020 Jan;21(1):145-161.
353. Million L, Hayes-Jordan A, Chi YY, Donaldson SS, Wolden S, Morris C, Terezakis S, Laurie F, Morano K, Fitzgerald TJ, Yock TI, Rodeberg DA, **Anderson JR**, Speights RA, Black JO, Coffin C, McCarville MB, Kao SC, Hawkins DS, Spunt SL, Randall RL. Local Control For High-Grade Nonrhabdomyosarcoma Soft Tissue Sarcoma Assigned to Radiation Therapy on ARST0332: A Report From the Children's Oncology Group. *Int J Radiat Oncol Biol Phys.* 2021 Jul 1;110(3):821-830.
354. Chesney JA, Ribas A, Long GV, Kirkwood JM, Dummer R, Puzanov I, Hoeller C, Gajewski TF, Gutzmer R, Rutkowski P, Demidov L, Arenberger P, Shin SJ, Ferrucci PF, Haydon A, Hyingstrom J, van Thienen JV, Haferkamp S, Guilera JM, Rapoport BL, VanderWalde A, Diede SJ, **Anderson JR**, Treichel S, Chan EL, Bhatta S, Gansert J, Hodi FS, Gogas H. Randomized, Double-Blind, Placebo-Controlled, Global Phase III Trial of Talimogene Laherparepvec Combined With Pembrolizumab for Advanced Melanoma. *J Clin Oncol.* 2023 Jan 20;41(3):528-540.
355. Robert C, Carlino MS, McNeil C, Ribas A, Grob JJ, Schachter J, Nyakas M, Kee D, Petrella TM, Blaustein A, Lotem M, Arance A, Daud AI, Hamid O, Larkin J, **Anderson J**, Krepler C, Grebennik D, Long GV. Seven-Year Follow-Up of the Phase III KEYNOTE-006 Study: Pembrolizumab Versus Ipilimumab in Advanced Melanoma. *J Clin Oncol.* 2023 Aug 20;41(24):3998-4003.

#### Chapters in Books

1. Sharp JG, Couse DA, Ullrich F, **Anderson J**, Vose J, Chan W, Wu G, Mann S, Reilly P, Blumel



- S, Inwards D, Loh K, Rifkin R. Autologous Blood and Marrow Transplantation, Proceedings of the 8th International Symposium. Dicke KA, Keating A, editors. Carden Jennings; 1997. Comparison of culture versus molecular detection of lymphoma in the context of a randomized prospective trial of blood versus marrow for reconstitution after high dose therapy: An interim analysis; p. 473-484.
2. Vose JM, **Anderson JR**, Bierman PJ, Armitage JO. Acute Leukemias: Experimental Approaches and Management of Refractory Diseases. W Hiddeman, T Buchne, B Worman, J Ritter U Creutzig, W Plunkett, editors. Fifth. Berlin, Germany: Springer-Verlag; 1996. Comparison of front-line chemotherapy for intermediate grade and follicular non-Hodgkin's lymphoma using the CAP-BOP regimens; p. 599-603.
  3. Schouten H, Sanger WG, Weisenburger DD, **Anderson JR**, Armitage JO. Chromosomal Abnormalities in Hematological Malignancies. Schouten H, editors. Koninklike Bibliotheek; 1991. Chromosome abnormalities in untreated patients with non-Hodgkin's lymphoma; p. 37-53.
  4. Byar DP, **Anderson JR**, Blumenstein B, Gibbons RP, Lepor H, Olsson CA, Simon R. Clinical Aspects of Prostate Cancer, Assessment of New Diagnostic and Management Procedures. Catalona WJ, Coffey DS, Karr JP, editors. New York, NY: Elsevier; 1989. Guidelines for reporting studies for prostate cancer

5. Ginsberg SJ, **Anderson JR**, Gottlieb AJ, Bloomfield CD, Norton L, Barcos M, Holland JF. NCI Monographs. National Cancer Institute; 1987. A Randomized trial of high dose methotrexate versus standard dose methotrexate following cyclophosphamide, adriamycin, vincristine, and prednisone with or without bleomycin in the therapy of advanced large cell lymphoma: Preliminary report of the Cancer; p. 77-80.
6. Jenkin R, **Anderson J**, Chilcote R, Coccia P, Exelby P, Kersey J, Kushner J, Meadows A, Siegel S, Wilson J, Leiken S, Hammond D. *Frontiers of Radiation Therapy and Oncology*. Vol. 16. Karger, Basel; 1982. Paediatric non-Hodgkin's lymphomas: The Children's Cancer Study Group Experience; p. 134-140.
7. Jenkin R, **Anderson J**, Chilcote R, Coccia P, Exelby P, Kersey J, Kushner J, Meadows A, Siegel S, Wilson J, Leiken S, Hammond D. *Malignant Lymphomas: Etiology, immunology, pathology, treatment*. New York, NY: Academic Press; 1982. Chapter 35, Paediatric non-Hodgkin's lymphomas: The Children's Cancer Study Group Experience; p. 591-601.
8. Siegal S, Jenkin D, Wilson J, **Anderson J**, Hammond D. *Cancer Achievements Challenges and Prospects for the 1980's*. New York, NY: Grune and Stratton; 1981. Long term survival in childhood non-Hodgkin's lymphoma; p. 225-236.
9. **Anderson J**, Krivit W, Thompson J, Chilcote R, Pysemany A, Hammond D. *Proceedings of the 11th International Congress of Chemotherapy/ 9th Interscience Conference on Antimicrobial Agents and Chemotherapy*. American Society for Microbiology; 1980. A study of the cross resistance of Vincristine and Vindesine in reinduction therapy for acute lymphocytic leukemia in relapse; p. 1567-1568.
10. Chilcote R, Krivit W, Pysemany A, Hammond D, **Anderson J**. *Sixth Vinca Alkaloid Symposium Vindesine*. Lilly Research; 1979. Induction of remission results using Vindesine in phase III studies for children who have relapsed from acute lymphocytic leukemia of childhood: A report from Childrens Cancer Study Group; p. 69-73. 11. Evans A, Anderson J, Chang C, Jenkin D, Kramer S, Schoenfeld D, Wilson C. *Proceedings of the Symposium on Multidisciplinary Aspects of Brain Tumor Therapy*. Elsevier/North-Holland Biomedical Press; 1979. Adjuvant chemotherapy for medulloblastoma and ependymoma; p. 219-222.

## Technical Reports/Other Publications

1. Chesney JA, Ribas A, Long GV, Kirkwood JM, Dummer R, Puzanov I, Hoeller C, Gajewski TF, Gutzmer R, Rutkowski P, Demidov L, Arenberger P, Shin SJ, Ferrucci PF, Haydon A, Hynstrom J, van Thienen JV, Haferkamp S, Guilera JM, Rapoport BL, VanderWalde A, Diede SJ, **Anderson JR**. Randomized, Double-Blind, Placebo-Controlled, Global Phase III Trial of Talimogene Laherparepvec Combined With *Pembrolizumab* for Advanced Melanoma. *J Clin Oncol.*, 2023 Jan 20;41(3):528-540.
2. Arnold MA, **Anderson JR**, Gastier-Foster JM, Barr FG, Skapek SX, Hawkins DS, Raney RB Jr, Parham DM, Teot LA, Rudzinski ER, Walterhouse DO. Histology, Fusion Status, and Outcome in Alveolar Rhabdomyosarcoma With Low-Risk Clinical Features: A Report From the Children's Oncology Group. *Pediatr Blood Cancer.* 2016 Jan 12.
3. Weigel BJ, Lyden E, **Anderson JR**, Meyer WH, Parham DM, Roderberg DA, Michalski JM, Hawkins DS, Arndt CA. Intensive Multiagent Therapy, Including Dose-Compressed Cycles of Ifosfamide/Etoposide and Vincristine/Doxorubicin/Cyclophosphamide, Irinotecan, and Radiation, in Patients With High-Risk Rhabdomyosarcoma: A Report From the Children's Oncology Group. *J Clin Oncol.* 2016 Jan 10; 34(2):117-22.
4. Wolden SL, Lyden ER, Amdt CA, Hawkins DS, **Anderson JR**, Rodeberg DA, Morris CD, Donaldson SS. Local Control for Intermediate-Risk Rhabdomyosarcoma: Results From D9803 According to Histology, Group, Site, and Size: A Report From the Children's Oncology Group. *Int J Radiat Oncol Biol Phys.* 2015 Dec 1; 93(5):1071-6.
5. Oberlin O, Rey A, Brown KL, Bisogno G, Koscielniak E, Stevvens MC, Hawkins DS, Meyer WH, La TH, Carli M, **Anderson JR**. Prognostic Factors for Outcome in Localized Extremity Rhabdomyosarcoma. Pooled Analysis from Four International Cooperative Groups. *Pediatr Blood Cancer.* 2015 Dec; 62(12); 2125-31.
6. Hingorani P, Missiaglia E, Shipley J, **Anderson JR**, Triche TJ, Delorenzi M, Gastier-Foster J, Wing M, Hawkins DS, Skapek SX. Clinical Application of Prognostic Gene Expression Signature in Fusion Gene-Negative Rhabdomyosarcoma: A Report from the Children's Oncology Group. *Clin Cancer Res.* 2015 Oct 15; 21(20): 4733-9.
7. Shiramizu B, Goldman S, Smith L, Agsalda-Garcia M, Galardy P, Perkins SL, Frazer JK, Sanger W, **Anderson JR**, Gross TG, Weinstein H, Harrison L, Barth MK, Mussolin L, Cairo MS. Impact of Persistent Minimal Residual Disease Post-Consolidation Therapy in Children and Adolescents With Advanced Burkitt Leukaemia: A Children's Oncology Group Pilot Study Report. *Br J Haematol.* 2015 Aug; 170(3):367-71.
8. Rudzinski ER, **Anderson JR**, Hawkins DS, Skapek SX, Parham DM, Teot LA. The World Health Organization Classification of Skeletal Muscle Tumors in Pediatric Rhabdomyosarcoma: A Report From the Children's Oncology Group. *Arch Pathol Lab Med.* 2015 Oct; 139(10):1281-7.
9. Maschietto M, Williams RD, Chagtai T, Popov SD, Sebire NJ, Vujanic G, Perlman E, **Anderson JR**, Grundy P, Dome JS, Pritchard-Jones K. TP53 Mutational Status is a Potential Marker for Risk Stratification in Wilms Tumour With Diffuse Anaplasia. 2014 Oct 14; 9(10):e109924.
10. McCarville MB, Muzzafar S, Kao SC, Coffin CM, Parham DM, **Anderson JR**, Spunt SL. Imaging Features of Alveolar Soft-Part Sarcoma: A Report From Children's Oncology Group Study ARST0332. *AJR Am J Roentgenol.* 2014 Dec; 203(6):1345-52.
11. Davis-Hall E, **Anderson JR**, Berndt WO, Bierman PJ, Haven MC, Helget V, Iwen PC, Froechle ML, Greiner CB, Daiser MM, Lenaghan P, Peck M, Raymond R, Romero J, Smith P, Stevens V, Zagurski R, Muellenberg P. Bioterrorism and Public Health Emergency Response Overview Module 1, US Dept. of Health and Human Services, Health Resource Service Administration, Bioterrorism and Public Health Emergency Course (CD). 2005.

## Abstracts

1. Ribas A, Chesney J, Long GV, Kirkwood JM, Dummer R, Puzanov I, Hoeller C, Gajewski TF, Gutzmer R, Rutkowski P, Demidov L, Arenberger P, Shin SJ, Ferrucci PF, Diederichs SJ, **Anderson J**, Treichel S, Chan EL, Hodi FS, Gogas H. MASTERKEY-265: A phase 3, randomized, placebo (Pbo)-controlled study of talimogene laherparepvec (T) plus pembrolizumab (P) for unresectable stage IIIB–IVM1c melanoma (MEL). ESMO 2021, T-VEC 265 Abstract.

2. La TH, Wolden SL, Su Z, Linardic CM, Randall RL, **Anderson J**, Hawkins D, Donaldson S. Local Therapy for Rhabdomyosarcoma of the Hands and Feet: Is There a Role for Amputation? A Report from the Children's Oncology Group. *Int J Radiat Onc.* 2009. Vol. 75. p. S40-S41.
3. Muelleman RL, Wadman MC, Tran TP, **Anderson JR**. Rural motor vehicle crash mortality rates are higher even when controlling for injury severity. *Acad Emerg Med.* 2004. Vol. 11 (5). p. 544-545.
4. Spunt SL, Meza JL, **Anderson JR**, Donaldson SS, Qualman SJ, Robison LL, Ruymann FB, Crist WM, Pappo AS. Second Malignant Neoplasms (SMNs) in Children Treated for Rhabdomyosarcoma: A Report from the Intergroup Rhabdomyosarcoma Studies (IRS) I-IV. *American Society of Clinical Oncology*; 2001.
5. Chiou RK, Carlson LK, Alberts GL, Anderson JC, Pomeroy BD, **Anderson JR**, Wobig RK. Color Doppler Sonography Study of Cavernous Artery Anatomy and Infarct on Hemodynamic Assessment. *Journal of Ultra.* 43rd Annual Convention of the American Institute of Ultrasound in Medicine; San Antonio, Texas. Mar 1999. Vol. 18. p. 541.
6. Freeman MB, Vose JM, **Anderson JR**, Kessinger A, Turner K, Bierman PJ, Armitage JO. Cost analysis of high dose chemotherapy and autologous transplantation for patients with non-Hodgkin's lymphoma. *ASCO* 16, 1468a; 1997.
7. Abou-Elella AA, Vose JM, **Anderson JR**, Bierman PJ, Greiner TC, Chan WC, Armitage JO, Weisenburger DD. Mediastinal large B-cell lymphoma: A clinicopathologic study of 50 cases. *Modern Pathology* 10, 119a; 1997.
8. Wu CD, Greiner TC, Vose JM, Gordon BG, **Anderson JR**, Chan WC, Morris SW, Weisenburger DD. Anaplastic large cell lymphoma in adults: A clinicopathologic study of 31 cases. *Modern Pathology* 10, 137a; 1997.
9. Pavletic ZS, Bishop MR, Tarantolo S, Nasrati K, Pirruccello SJ, Zhang G, Bierman PJ, Reed EC, Vose JM, Armitage JO, **Anderson JR**, Joshi SS, Kessinger A. Immunological recover following allogeneic transplantation with peripheral blood stem cells. *ASH - Blood* 86; 403a; 1995.
10. Kessinger A, **Anderson JR**, Bishop M, Vose JM, Bierman PJ, Armitage JO. Lymphoma patients who require platelet transfusions during blood stem cell collection have slower platelet recovery after high dose therapy and autotransplant. *ASH - Blood* 86; 397a; 1995.
11. Vose JM, Bierman PJ, Sanger W, Bast M, **Anderson JR**, Bishop M, Kessinger A, Armitage JO. High dose chemotherapy and autologous hematopoietic transplantation for follicular lymphoma: Incidence of post-transplant clonal myelodysplastic changes. *ASCO* 14; 1208a; 1995.
12. Bishop MR, Vose JM, Bierman PJ, Cowles K, **Anderson JR**, Kessinger A, Armitage JO. A comparison of peripheral blood versus bone marrow autografting following high dose therapy in patients with malignant lymphomas. *ASCO* 14; 1207a; 1995.
13. Watanabe T, Bishop MR, **Anderson JR**, Petersen KA, Jackson JD, Vose JM, Bierman PJ, Armitage JO, Reed EC, Tarantolo S, Kessinger A. Predictors for granulocyte-macrophage colony-stimulating factor mobilized peripheral stem cell yield and time to engraftment following transplantation. *Experimental Hematology* 22:8 Abst #387; 1994.
14. Martin-Algarra S, Bierman PJ, **Anderson J**, Vose JM, Kessinger A, Armitage JO. Cyclophosphamide, BCNU and VP-16 followed by autologous bone marrow or peripheral blood stem cell transplantation in Hodgkin's disease. Retrospective analysis of 10 years experience at the University of Nebraska Medical Center. *ASH - Blood* 84; 2131a; 1994.
15. Kessinger A, **Anderson JR**, Bierman PJ, Vose JM, Bishop MR, Armitage JO. Mobilized versus non-mobilized peripheral stem cell transplantation after high dose therapy for low grade non-Hodgkin's lymphoma: Effect on progression free survival. *ASH - Blood* 84; 1568a; 1994.
16. Vose JM, Ruby E, Bierman PJ, **Anderson JR**, Weisenburger DD, Armitage JO. Elderly patients with localized diffuse large cell non-Hodgkin's lymphoma: Improved results with initial chemotherapy. *ASH - Blood* 84; 1519a; 1994.
17. Bierman PJ, **Anderson JR**, Vose JM, Slowiaczek K, Morris M, Armitage JO. Effect of a delay in starting chemotherapy for patients with diffuse large cell non-Hodgkin's lymphoma. *ASH - Blood* 84; 644a; 1994.

18. Kessinger A, **Anderson JR**, Armitage JO, Bierman PJ, Bishop MR, Reed EC, Tarantolo S, Vose JM. Effect of GM-CSF administration after transplantation of GM-CSF mobilized autologous peripheral stem cells for patients treated with high dose cyclophosphamide and total body irradiation. *ASH - Blood* 84; 362a; 1994.
19. Martin-Algarra S, Bishop MR, Tarantolo S, Reed EC, **Anderson JR**, Vose JM, Bierman PJ, Armitage JO, Kessinger A. Early administration of cytokines after related allogeneic bone marrow transplantation for hematological malignancies reduces duration of aplasia, hospital stay and treatment related mortality. *ASH - Blood* 84; 359a; 1994.
20. Vose JM, Byar K, **Anderson JR**, Bierman PJ, Bishop MR, Kessinger A, Armitage JO. SPECT gallium imaging: More predictive than computed tomography of clinical outcome following high dose chemotherapy and transplant for diffuse large cell non-Hodgkin's lymphoma. *ASCO* 13; 1259a; 1994.
21. Jain B, Floreani AA, **Anderson JR**, Vose JM, Vaughan W, Robbins RA, Rennard SI, Sisson JH. Predictive value of exercise tolerance and pulmonary function tests for respiratory failure and short term mortality in lymphoma patients undergoing autologous bone marrow transplantation. *American Thoracic Society*; May 1994.
22. Martin AR, Weisenburger DD, Vose JM, **Anderson JR**, Bierman PJ, Bast MA, Daley DT, Armitage JO, Chan WC. Prognostic value of cellular proliferation in follicular lymphoma studied by image analysis of fixed tissue stained with Ki-67. *IAP*; 1994.
23. Kessinger A, Bishop MR, Jackson J, **Anderson JR**, Murphy B, Vose JM, et al. Erythropoietin for mobilization of circulating progenitor cells in patients with previously treated malignancies. *ASH - Blood* 82; 892a; 1993.
24. Bennett CL, Armitage JO, Schwartz CE, Bierman PJ, Vose JM, **Anderson JR**. A learning curve exists in autologous transplantation for Hodgkin's disease and NHL as evidenced by improvements in cost and in-hospital mortality. *ASH - Blood* 82; 571a; 1993.
25. Vose JM, Weisenburger DD, **Anderson JR**, et al. Mantle cell lymphoma has poorer prognosis than follicular non-Hodgkin's lymphoma; however, high dose therapy and autologous stem cell transplantation may overcome treatment resistance in MCL. *ASH - Blood* 82; 527a; 1993.
26. Bierman PJ, Vose JM, **Anderson JR**, Bishop MR, Pierson J, Armitage JO, Kessinger A. Comparison of autologous bone marrow transplantation with peripheral stem cell transplantation for patients with Hodgkin's disease. *ASH - Blood* 82; 1765a; 1993.
27. Vose JM, Bierman PJ, **Anderson JR**, Bishop MR, Kessinger A, Armitage JO. High dose chemotherapy and autologous hematopoietic rescue for intermediate grade non-Hodgkin's lymphoma: Comparison of clinical outcome for patients receiving an autologous bone marrow or peripheral stem cell graft. *Third International Symposium on Peripheral Stem Cell Autografts*; Bordeaux, France. Oct 1993.
28. Vose JM, Darrington D, Bierman PJ, Bishop MR, **Anderson JR**, Kessinger A, Armitage JO. Myelodysplastic syndrome, acute myelogenous leukemia following high dose chemotherapy and autologous stem cell transplantation for lymphoid malignancy: Characterization and relative risk. *Fifth International conference on malignant lymphoma*; 1993.
29. Armitage JO, Vose JM, **Anderson JR**, Bierman PJ, Bishop MR, Kessinger A. Complete remission following high dose chemotherapy and autologous hematopoietic rescue for non-Hodgkin's lymphoma: Evaluation of CR durability and incidence of secondary myelodysplastic syndrome. *ASCO* 12; 1225 a; 1993.
30. Vose JM, **Anderson JR**, Bierman PJ, Garrison L, Appelbaum F, Anderson J, Bishop MR, Larsen K, Armitage JO. Initial trial of PIXY321 (GM-CSF/UL-3 Fusion Protein) following high dose chemotherapy and autologous bone marrow transplantation for lymphoid malignancy. *ASCO* 12; 1237a; 1993.
31. Bierman PJ, **Anderson JR**, Vose JM, Freeman M, Bishop MR, Kessinger A, Armitage JO. High dose chemotherapy followed by autologous hematopoietic rescue following first relapse of Hodgkin's disease. *ASCO* 12, 1238a; 1993.

32. **Anderson JR**, Jenkin RDT, Wilson JF, Kjeldsberg CR, Sposto R, Chilcote RR, Coccia P, Exelby P, Siegal S, Meadows AT, Hammond GD. for the Children's Cancer Group Long-term follow-up of Patients treated with COMP or LSA2L2 therapy for childhood non-Hodgkin's Lymphoma. Fifth International Conference on Malignant Lymphoma at Lugano; Lugano. Jun 1993.
33. Kessinger A, Jackson J, **Anderson JR**, Vose JM, Bierman PJ, Armitage JO. High dose therapy and autologous peripheral stem cell transplantation for low grade non-Hodgkin's lymphoma: Effect of GM-CSF on the autograft. *ASH - Blood* 80; 1318a; 1992.
34. Vose JM, **Anderson JR**, Bierman PJ, Bast MA, Weisenburger DD, Chan WC, Armitage JO. Comparison of front line chemotherapy for aggressive non-Hodgkin's lymphoma using CAP-BOP with adriamycin, adriamycin and infusional bleomycin/vincristine or mitoxantrone. *ASH - Blood* 80; 162a; 1992.
35. Vose JM, Armitage JO, **Anderson JR**, Bierman PJ, Pierson J, Coccia P, Kessinger A, Gordon B, Reed EC, Warkentin P. High dose chemotherapy with hematopoietic stem cell rescue for non-Hodgkin's lymphoma: Evaluation of event free survival based on histologic subtype and rescue product. *ASCO* 11; 318a; 1992.
36. Dumonet C, **Anderson JR**, Sebban C, Biron P, Tirelli U, Vose JM, Armitage JO, Coiffier B. Elderly non-Hodgkin's lymphoma patients have comparable prognostic factors but a poorer outcome than younger patients. *ASCO* 11; 328a; 1992.
37. **Anderson JR**, Weisenburger DD, Vose JM, Bierman PJ, Sanger W, Pierson J, Bast MA, Armitage JO. Clinical features and prognosis of follicular large cell lymphoma: A report from the Nebraska Lymphoma Study Group. *ASCO* 11; 330a; 1992.
38. Gordon B, Weisenburger DD, Warkentin P, **Anderson JR**, Sanger W, Bast MA, Gnarra D, Vose JM, Bierman PJ, Armitage JO, Coccia P. Peripheral T-cell lymphoma in childhood: A clinicopathologic study of 22 patients. *ASH - Blood* 78; 175a; 1991.
39. Gordon B, Warkentin P, Weisenburger DD, Vose JM, Sanger W, Strandjord S, **Anderson JR**, Verdirame J, Bierman PJ, Armitage JO, Coccia P. Bone marrow transplantation for relapsed peripheral T-cell lymphoma in children and young adults. *ASH - Blood* 78; 237a; 1991.
40. Vose JM, Pipert G, Reed, **Anderson JR**, Bierman PJ, Kessinger A, Armitage JO. Randomized trial comparing mesna to bladder irrigation for the prevention of hemorrhagic cystitis with high dose cyclophosphamide and bone marrow transplantation. *ASH - Blood* 78; 247a; 1991.
41. Vose JM, Bierman PJ, **Anderson JR**, Weisenburger DD, Armitage JO. CHLVPP plus involved field irradiation for Hodgkin's disease: Comparable results with less toxicity. *ASCO* 10, 272a, Abst #944; 1991.
42. Sisson JH, **Anderson JR**, Robbins RA, Thompson AB, Spurzem JR, Armitage JO, Vaughn WP, Reed EC, Rennard SI. Airway inflammation prior to autologous bone marrow transplantation predicts the occurrence of diffuse alveolar hemorrhage. *European Respira*. Apr 1991. Vol. 4. p. 42S-43S.
43. Jenkin RDT, **Anderson JR**, Chilcote RR, Coccia P, Exelby PR, Kersey JH, Kushner JH, Meadows AT, Siegel SE, Sposto R, Wilson JF, Hammond GD. The treatment of non-lymphoblastic (NLB) non-Hodgkin's lymphoma (NHL) in children. International Symposium on Burkitt's lymphoma A Human Cancer Model World Health Organization; 1983.